

CIVIL COVER SHEET

JS 44 (Rev. 11/04)

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

I. (a) PLAINTIFFS

RoyaltyStat, LLC

DEFENDANTS

IntangibleSpring Corporation, et al.

(b) County of Residence of First Listed Plaintiff Montgomery

(EXCEPT IN U.S. PLAINTIFF CASES)

County of Residence of First Listed Defendant

(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE LAND INVOLVED.

(c) Attorney's (Firm Name, Address, and Telephone Number)

DiMuroGinsberg PC, 1101 King Street, Suite 610, Alexandria, VA 22314, 703-684-4333

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
- ☒ 3 Federal Question (U.S. Government Not a Party)
- ☐ 2 U.S. Government Defendant
- ☒ 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | PTF | DEF | | PTF | DEF |
|---|---------------------------------------|---------------------------------------|---|---------------------------------------|----------------------------|
| Citizen of This State | <input checked="" type="checkbox"/> 1 | <input type="checkbox"/> 1 | Incorporated or Principal Place of Business In This State | <input checked="" type="checkbox"/> 4 | <input type="checkbox"/> 4 |
| Citizen of Another State | <input type="checkbox"/> 2 | <input type="checkbox"/> 2 | Incorporated and Principal Place of Business In Another State | <input type="checkbox"/> 5 | <input type="checkbox"/> 5 |
| Citizen or Subject of a Foreign Country | <input type="checkbox"/> 3 | <input checked="" type="checkbox"/> 3 | Foreign Nation | <input type="checkbox"/> 6 | <input type="checkbox"/> 6 |

IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS		FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excl. Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise	PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input checked="" type="checkbox"/> 360 Other Personal Injury	PERSONAL INJURY <input type="checkbox"/> 362 Personal Injury - Med. Malpractice <input type="checkbox"/> 365 Personal Injury - Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Product Damage Product Liability	<input type="checkbox"/> 610 Agriculture <input type="checkbox"/> 620 Other Food & Drug <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 630 Liquor Laws <input type="checkbox"/> 640 R.R. & Truck <input type="checkbox"/> 650 Airline Regs. <input type="checkbox"/> 660 Occupational Safety/Health <input type="checkbox"/> 690 Other	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input checked="" type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark	<input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 810 Selective Service <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 875 Customer Challenge 12 USC 3410 <input checked="" type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 892 Economic Stabilization Act <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 894 Energy Allocation Act <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 900 Appeal of Fee Determination Under Equal Access to Justice <input type="checkbox"/> 950 Constitutionality of State Statutes
REAL PROPERTY <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	CIVIL RIGHTS <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 444 Welfare <input type="checkbox"/> 445 Amer. w/Disabilities - Employment <input type="checkbox"/> 446 Amer. w/Disabilities - Other <input type="checkbox"/> 440 Other Civil Rights	PRISONER PETITIONS <input type="checkbox"/> 510 Motions to Vacate Sentence Habeas Corpus: <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty <input type="checkbox"/> 540 Mandamus & Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition	LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Mgmt. Relations <input type="checkbox"/> 730 Labor/Mgmt. Reporting & Disclosure Act <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Empl. Ret. Inc. Security Act	SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609	

V. ORIGIN

(Place an "X" in One Box Only)

- ☒ 1 Original Proceeding
- ☐ 2 Removed from State Court
- ☐ 3 Remanded from Appellate Court
- ☐ 4 Reinstated or Reopened
- ☐ 5 Transferred from another district (specify)
- ☐ 6 Multidistrict Litigation
- ☐ 7 Appeal to District Judge from Magistrate Judgment

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):

17 USC 101, et seq, 15 USC 1125(a)
Brief description of cause: Copyright, false advertising, misappropriation of trade secrets, breach of fiduciary duties, and injunctive relief**VII. REQUESTED IN COMPLAINT:**☐ CHECK IF THIS IS A CLASS ACTION UNDER F.R.C.P. 23**DEMAND \$**

CHECK YES only if demanded in complaint:

JURY DEMAND: ☐ Yes ☒ No**VIII. RELATED CASE(S) IF ANY**

(See instructions):

JUDGE

DOCKET NUMBER

DATE

12/23/2015

SIGNATURE OF ATTORNEY OF RECORD

/s/ Billy B. Ruhling, II

FOR OFFICE USE ONLY

RECEIPT #

AMOUNT

APPLYING IFP

JUDGE

MAG. JUDGE

widely recognized around the world because Dr. Silva has invested in quality control and promoting the RoyaltyStat brand.

2. RoyaltyStat has invested several million dollars in developing and promoting its database, and continues to invest over a million dollars each year to maintain the high quality product and customer service that RoyaltyStat's clients and potential clients have come to expect.

3. In the spring of 2013, however, RoyaltyStat's primary competitor noticed a new-comer to the intangible license/tax field and brought it to Dr. Silva's attention. Most significantly, this new business, IntangibleSpring, Corp. ("IntangibleSpring") boasted it possessed the same client list as RoyaltyStat, and began asserting it provided the same data provided by RoyaltyStat at a significantly lower cost.

4. Alerted to this information, RoyaltyStat began investigating IntangibleSpring and learned that it was started by one of RoyaltyStat's own former independent contractors, Raul Pacheco Quintanilla ("Mr. Pacheco"). Further investigation revealed that Mr. Pacheco, immediately prior to being terminated by RoyaltyStat, accessed its data files and stole RoyaltyStat's proprietary data, which he used to form a competitor business under the name IntangibleSpring.

5. IntangibleSpring's misappropriation of RoyaltyStat's trade secrets and proprietary data significantly eroded RoyaltyStat's profits. Moreover, its false advertising claims have lured clients from RoyaltyStat, thereby causing irreparable harm. By relying upon and incorporating RoyaltyStat's data, IntangibleSpring violated federal and state laws. This action seeks redress for these injuries.

JURISDICTION AND VENUE

6. This Court has jurisdiction over this case pursuant to 28 U.S.C. §§ 1331, 1332(a)(2) and 1338.

7. Venue is proper in this Court pursuant to 28 U.S.C. § 1391(b)(2).

PARTIES

8. RoyaltyStat LLC is a limited liability company formed under the laws of the State of Maryland with its principal place of business at 5335 Wisconsin Avenue, N.W., Suite 920, Washington, D.C. 20015-2084, on the border of Maryland and Washington D.C.

9. IntangibleSpring, Corp. is a corporation organized under the laws of Panama with its principal place of business in Panama City, Panama. Defendant Raul Pacheco Quintanilla is a principal in IntangibleSpring. The company provides a database of royalty rates ostensibly based upon unredacted license agreements filed with the United States Securities & Exchange Commission (“SEC”). IntangibleSpring claims to provide a website featuring non-downloadable software for analyzing and evaluating the value of intangible property such as royalties and license fees. IntangibleSpring apparently hosts its website, www.intangiblespring.com, through a domain host located in Houston, Texas.

10. Upon information and belief, Raul Pacheco Quintanilla is a citizen of Brazil and Mexico. He resides at various times throughout the year in either France, Belo Horizonte, Brazil, or Mexico City, Mexico. Upon information and belief, Mr. Pacheco runs IntangibleSpring, and makes claims to such effect in the business network LinkedIn. Because Mr. Pacheco takes affirmative steps to avoid disclosing his precise location, RoyaltyStat is unable to effect service of process and names him herein as if he was a “John Doe” defendant. Once his precise location can be ascertained, RoyaltyStat intends to effect service of process and join Mr. Pacheco herein.

FACTUAL ALLEGATIONS COMMON TO ALL COUNTS

RoyaltyStat LLC Offers Unrivaled Access to License Agreement Data and Analysis

11. Since launching its online presence on February 2, 2000, RoyaltyStat has provided to paid subscribers a reliable source of royalty rates extracted from unredacted license agreements. An unredacted license agreement contains disclosed royalty rate information, and other monetary licensing consideration, such as upfront and milestone payments. A large percentage of material license agreements filed with the SEC are redacted to remove critical information such as the royalty rate, upfront fees, minimum license fees, and other forms of monetary compensation. This information can be very valuable to government tax administrations and to corporate taxpayers complying with the arm's length standard of IRC section 482, and complying with similar standards under the OECD (Organization for Economic Cooperation and Development). RoyaltyStat has expended and continues to expend a great deal of effort and money to identify and obtain unredacted agreements, and to extract searchable data fields from them. The information RoyaltyStat makes available to paid subscribers is used in transfer pricing, purchase price allocation, intellectual property valuation, and for due diligence connected with litigation, corporate bankruptcy, business development, and mergers and acquisitions.

12. RoyaltyStat's online database of license agreements represents a significant investment in time and money over the course of its 20 year business history. Many of the license agreements in the collection can only be obtained through exhaustive public record searches or by submission of Freedom of Information Act ("FOIA") requests.

13. Full access (*e.g.*, the capability to search for comparables, read records, select comparable records to the taxpayer's intangible property, and download data) is tightly

controlled within RoyaltyStat. Only a limited number of authorized employees and contractors have been given such access. Mr. Pacheco was among those given such access while he was supposed to be working exclusively for RoyaltyStat.

14. All of RoyaltyStat's employees and contractors have been required to sign confidentiality/non-disclosure agreements as a condition of receiving access to the database. Sometime in 2009 RoyaltyStat asked its employees and contractors to re-execute these agreements.

15. RoyaltyStat has a client base of more than 200 subscribers ranging from corporations to government agencies to professional services firms (*e.g.*, law firms and international accounting firms). RoyaltyStat's client list is also closely guarded. RoyaltyStat has never made its customer list public and restricts access to the information to certain employees and contractors of the company on a need-to-know basis.

16. RoyaltyStat's subscribers, who pay an annual subscription fee, can search its unique proprietary online database containing more than 16,500 unredacted license agreements to identify comparable royalty rates by selecting filters, including Standard Industrial Classification ("SIC") codes, intangible property type (copyright, patent, trademark), and keywords. In addition, subscribers get access to financial information and annual reports for more than 34,000 publicly traded companies.

17. In order to keep its database current, RoyaltyStat is one of the most prolific filers of FOIA requests. Because so much of the data in its database can only be compiled from information that is only available through this laborious and expensive process, a significant time commitment and investment were and are necessary to build and maintain the database to its current level.

18. Before receiving access to the RoyaltyStat database, subscribers must execute a Subscription Agreement.

19. The Subscription Agreement expressly prohibits subscribers from “modify[ing], decompil[ing], disassembl[ing], or reverse engineer[ing] RoyaltyStat, the License Agreements Database, its process, its content, or any portion thereof.” RoyaltyStat Subscription Agreement, ¶ 5.6.

20. Further the Subscription Agreement expressly prohibits subscribers from “assembl[ing] or us[ing] the License Agreements Database, or any data or documents obtained from the License Agreements Database, in any manner that violates RoyaltyStat’s copyrights or that competes with, substitutes for, or is an alternative to RoyaltyStat’s subscription services.” *Id.*, ¶ 5.7.

21. In addition, by signing the Subscription Agreement, subscribers acknowledged and agreed that “RoyaltyStat, the License Agreements Database, its process, its content, and any portion thereof constitute and contain valuable proprietary information and trade secrets of RoyaltyStat and/or its suppliers, embodying substantial creative efforts and confidential information, ideas, and expressions. Accordingly, Subscriber[s] agree[s] to treat (and take precautions to ensure that [their] employees treat) RoyaltyStat, the License Agreements Database, its process, its content, and any portion thereof as confidential and to exercise at all times a reasonable degree of care in the protection of confidential information.” *Id.*, ¶ 8.

22. Each of these controls was put in place to protect RoyaltyStat’s copyrights and trade secrets.

Raul Pacheco Quintanilla's Relationship to RoyaltyStat LLC

23. From 1982 until 1990, Ednaldo Silva served as a very successful and well-regarded professor of economics on the Graduate Faculty of the New School for Social Research in New York City. While teaching, he became a dissertation advisor to Claudio Gontijo. As a result of this relationship, Dr. Silva developed a long standing personal relationship with Dr. Gontijo's stepson, Mr. Pacheco.

24. In 2000, Dr. Silva offered Mr. Pacheco an internship working with RoyaltyStat. Subsequently, working as an outside contractor, Mr. Pacheco began as a reader extracting data fields from license agreements that RoyaltyStat purchased. Ultimately, Mr. Pacheco began working in customer service and sales. In both capacities, he was given unlimited access to the RoyaltyStat License Agreements Database, its process, its content, and its trade secrets. As a result of the unfettered access he was given to this confidential and proprietary information, Mr. Pacheco owed a fiduciary duty of loyalty to RoyaltyStat.

25. Mr. Pacheco's primary responsibility at RoyaltyStat was to sell new subscriptions and to provide customer service to subscribers. For each subscription he sold, Mr. Pacheco was obligated to obtain an executed Subscription Agreement and he was required to ensure such subscribers understood the limitations of use embodied in the Subscription Agreement as set forth *supra*.

26. For each such subscription sold, Mr. Pacheco received a commission. His right to payment continued for periodic customer service functions he performed related to renewals of all subscriptions, including those he had sold.

27. In late 2009, RoyaltyStat learned that Mr. Pacheco was embezzling funds from the company by having certain Latin American subscription fees routed to his personal account in Mexico, instead of going to RoyaltyStat's account in the U.S.

28. On September 23, 2011, RoyaltyStat terminated its relationship with Mr. Pacheco for cause, including abandonment of customer support work, deception, and failure to sell new subscriptions.

Raul Pacheco and IntangibleSpring Misappropriated RoyaltyStat's Trade Secrets

29. Even before his termination, Mr. Pacheco began sowing the seeds of his efforts to undermine RoyaltyStat. On December 1, 2010, Mr. Pacheco accessed and downloaded/exported RoyaltyStat's database data into an Excel spreadsheet. On two other occasions, December 14, 2010 and January 28, 2011, he stole additional data from RoyaltyStat.

30. On three additional dates, Mr. Pacheco accessed RoyaltyStat's back-office library and downloaded unredacted license agreements collected by RoyaltyStat not for use in connection with performing his duties to RoyaltyStat, but to use for his own personal gain.

31. All of these items that Mr. Pacheco downloaded were protected trade secrets. They were only accessible for download using access afforded to a strictly limited and tightly controlled number of persons associated with RoyaltyStat, and were only allowed to be downloaded to perform assigned quality control tasks on behalf and for the sole benefit of RoyaltyStat. The information Mr. Pacheco purloined could not be downloaded from RoyaltyStat's database or servers using a client access login. It required back-office access using an additional administrative login.

32. Having stolen RoyaltyStat's proprietary and confidential trade secrets, Mr. Pacheco set out to establish a company that would compete directly against RoyaltyStat. On August 8, 2012, IntangibleSpring Corp. was formed in Panama.

33. RoyaltyStat first learned of IntangibleSpring's existence in April 2013 when a competitor, contacted Dr. Silva to alert him. At that time the competitor advised RoyaltyStat that, to the competitor's surprise, IntangibleSpring had RoyaltyStat's customer list and had almost precisely the same number of records in its database as RoyaltyStat had as of the time Mr. Pacheco was fired. Not coincidentally, the number of records cited by the competitor was almost identical to the number of records stolen by Mr. Pacheco on the dates, identified above.

34. RoyaltyStat's customer list was not publicly available at that time, or any time before or thereafter.

35. By April 19, 2013, IntangibleSpring claimed that its database contained more than 10,500 records. IntangibleSpring falsely claimed to be adding more than 600 records per month.

36. Upon information and belief, IntangibleSpring and Mr. Pacheco have falsely claimed to offer the same data and analysis that is the same or substantially the same in quality and content as that provided by RoyaltyStat.

37. The only analysis IntangibleSpring offers comparable to that provided by RoyaltyStat has been stolen from RoyaltyStat.

38. For example, some of IntangibleSpring's database records contain content copied verbatim from RoyaltyStat. As reflected in Exhibits A and B, a comparison of database data from the two companies reveals identical sentence structure and punctuation in both databases. Such similarity can only occur by rote copying from one source to another because the text at

issue was drafted by RoyaltyStat personnel analyzing source agreements. The cited text does not appear in the original source agreements filed with the SEC.

39. Further, some of these records in IntangibleSpring's database containing content copied verbatim from RoyaltyStat correspond to records added to RoyaltyStat's database after September 2013. IntangibleSpring could only have obtained the copied material in conjunction with someone possessing access to RoyaltyStat's database. Such person necessarily must be either RoyaltyStat personnel or a RoyaltyStat customer. In either case, the individual IntangibleSpring obtained the information from could only provide the information in violation of a confidentiality agreement.

40. Mr. Pacheco has contacted several of RoyaltyStat's customers and offered subscriptions of stolen data for about 1/3 of the RoyaltyStat regular subscription price. Several former RoyaltyStat customers who switched to IntangibleSpring, who are reputable businesses have confirmed that they would not have switched except for the deception and significantly lower prices offered by Mr. Pacheco.

41. By misrepresenting the product it offers as being comparable in content, but lower in price to that provided by RoyaltyStat, IntangibleSpring has enticed some of RoyaltyStat's customers to switch to its service. This has caused RoyaltyStat to lose significant revenue and profits.

COUNT I:

VIOLATION OF THE COPYRIGHT ACT, 17 U.S.C. § 101 ET SEQ.

42. RoyaltyStat incorporates paragraphs 1-40 as if fully set forth herein.

43. RoyaltyStat is the owner of all rights, title and interest in and to the copyrights in its database. RoyaltyStat's database is the subject of U.S. Copyright Registration

TX0007233781, dated May 7, 2009 (the “’781 Registration”). A copy of the ‘781 Registration as obtained from the U.S. Copyright Office’s online records is attached as Exhibit C. The RoyaltyStat database is also the subject of U.S. Copyright Application entitled “RoyaltyStat Royalty Tableau,” which was filed with the U.S. Copyright Office on December 21, 2015 (the “Royalty Tableau Application”). A copy of the Royalty Tableau Application as filed is enclosed as Exhibit D.

44. RoyaltyStat’s copyrights protect the original expression in (a) the selection, coordination and arrangement involved in choosing material and data for inclusion in the database; classifying, categorizing, ordering, or grouping the material and data; and determining the placement and arrangement of material and data within the database as a whole; and (b) RoyaltyStat’s original authorship, such as original textual content, that appears within the database.

45. Defendant Raul Pacheco Quintanilla had access to and copied RoyaltyStat’s original authorship which was then used by Mr. Pacheco and Defendant IntangibleSpring to create the IntangibleSpring database. The IntangibleSpring database contains text, material and data that is substantially similar, if not identical, to that of RoyaltyStat’s original authorship in its database.

46. Defendants have thus reproduced, prepared a derivative work based on, and/or distributed RoyaltyStat’s copyrighted work, including the original expression identified above and covered by the ‘781 Registration and Royalty Tableau Application. Defendants’ actions have been without RoyaltyStat’s permission or authority, and violate RoyaltyStat’s exclusive rights in its original work of authorship. Defendants’ actions therefore constitute copyright infringement pursuant to the Copyright Act, 17 U.S.C. § 501.

47. RoyaltyStat has been damaged by Defendants' infringement, including suffering harm for which there is no adequate remedy at law.

48. RoyaltyStat is entitled to an award of either statutory or actual damages suffered by it as a result of Defendants' infringement, and any profits of Defendants that are attributable to the infringement. RoyaltyStat is also entitled to entry of an injunction against further violations of RoyaltyStat's copyrights by Defendants.

COUNT II:

FALSE ADVERTISING IN VIOLATION OF THE LANHAM ACT, 15 USC § 1125(a).

49. RoyaltyStat incorporates paragraphs 1-48 as if fully set forth herein.

50. Upon information and belief, Defendants' have represented to their clients and potential clients, including those who are current or former clients of RoyaltyStat, that IntangibleSpring's database is the same as RoyaltyStat's in content and quality, but is offered for a lower price. RoyaltyStat devotes substantial resources to updating its database and assuring that the data is of the highest integrity. As a result of these substantial efforts over many years, RoyaltyStat and its founder, Dr. Silva, have developed a reputation for the high-quality of the RoyaltyStat database. Apart from portions of RoyaltyStat's database that they have copied, Defendants have not and cannot maintain a database of similar quality. Defendants' cannot therefore offer a database product that is similar to RoyaltyStat's in content and quality for a lower price.

51. Defendants' statements constitute a false and misleading representation of fact regarding the nature and quality of both the RoyaltyStat database and the IntangibleSpring database. Defendants' actions were undertaken to deliberately trade on the goodwill and reputation RoyaltyStat has developed as a result of the high quality of its product and services.

Defendants' actions therefore constitute unfair competition and false advertising pursuant to § 43(a) of the Lanham Act, 15 U.S.C § 1125(a).

52. Defendants' actions have been undertaken willfully and with a deliberate intent to deceive.

53. RoyaltyStat has suffered damages as a result of Defendants' actions, including harm for which there is no adequate remedy at law.

54. RoyaltyStat is therefore entitled to recover Defendants' profits, damages sustained by it, increased up to three times, costs of this action, and RoyaltyStat's attorney fees.

RoyaltyStat is also entitled to entry of an injunction against further violations by Defendants.

COUNT III:

VIOLATION OF THE MARYLAND UNIFORM TRADE SECRETS ACT

55. RoyaltyStat incorporates paragraphs 1-54 as if fully set forth herein.

56. RoyaltyStat's customer list, its License Agreements Database, its process, and its content each constitutes and contains valuable proprietary information and trade secrets of RoyaltyStat.

57. At all times relevant hereto, RoyaltyStat took reasonable measures designed to protect the confidentiality of its trade secrets. Among the measures employed, RoyaltyStat controlled access and disclosure through, *inter alia*:

- a. Controlling access to its database through assigned login/password combinations;
- b. Limiting the scope of access to persons based upon the level of access required for their respective purpose;
- c. Requiring employees and contractors to execute confidentiality and/or non-disclosure agreements;

- d. Requiring customers to execute Subscription Agreements containing confidentiality and non-disclosure provisions;
- e. Controlling and limiting access to its customer list.

58. RoyaltyStat derives independent economic value from its trade secrets inasmuch as subscribers pay for the service for the sole purpose of receiving access to the substantial creative efforts and confidential information, ideas and expressions appearing in its License Agreements Database.

59. Raul Pacheco Quintanilla and IntangibleSpring misappropriated RoyaltyStat's trade secrets by using the information Mr. Pacheco downloaded from RoyaltyStat's database and publishing the same as if it was IntangibleSpring's own work product in direct competition with RoyaltyStat.

60. Raul Pacheco Quintanilla's and IntangibleSpring's wrongful actions proximately caused RoyaltyStat to suffer injury in the form of, *inter alia*, lost subscription revenue and profits.

COUNT IV:

TORTIOUS INTERFERENCE WITH CONTRACT

61. RoyaltyStat incorporates paragraphs 1-60 as if fully set forth herein.

62. RoyaltyStat had existing contracts with customers obligating them to protect the confidentiality of RoyaltyStat's proprietary information and trade secrets as defined in the Subscription Agreement.

63. RoyaltyStat's employees and contractors all executed, and are bound by, non-disclosure and non-competition agreements that obligate the employees to protect the confidentiality of RoyaltyStat's proprietary information and trade secrets.

64. Raul Pacheco Quintanilla and IntangibleSpring knew or should have known of the obligations imposed on RoyaltyStat's customers by virtue of the Subscription Agreement.

65. Raul Pacheco Quintanilla and IntangibleSpring knew or should have known of the obligations imposed on RoyaltyStat's employees and contractors by virtue of the non-disclosure and non-competition agreements such persons executed in the course of their employment.

66. Raul Pacheco Quintanilla and IntangibleSpring tortiously interfered with RoyaltyStat's contracts by inducing one or more of RoyaltyStat's subscribers or employees, after Mr. Pacheco was no longer associated with RoyaltyStat, to provide him with copies of RoyaltyStat database content.

67. The defendants' actions are the direct and proximate cause of significant injury to RoyaltyStat in an amount to be proved at trial.

REQUEST FOR PERMANENT INJUNCTION

68. RoyaltyStat incorporates paragraphs 1-67 as if fully set forth herein.

69. As detailed above, the defendants' wrongful actions are causing, and will continue to cause irreparable injury to RoyaltyStat in the form of loss of goodwill and reputation, loss of business opportunities, and price erosion, in a manner for which there is no adequate remedy at law.

70. RoyaltyStat therefore seeks, and is entitled to, an order enjoining the defendants from using, publishing, or selling any of RoyaltyStat's data, proprietary information, or trade secrets on the internet or in any other form.

71. RoyaltyStat will suffer irreparable harm if the relief sought herein is not granted.

72. Because of the unique nature of the injuries caused by the defendants' wrongful actions, RoyaltyStat has no adequate remedy at law.

WHEREFORE, the Plaintiff, RoyaltyStat, LLC, requests:

- A. That this Court award compensatory damages jointly and severally against the defendants in an amount equal to the value of RoyaltyStat's actual damages and/or defendants' profits resulting from the violation of RoyaltyStat's intellectual property rights;
- B. That this Court award statutory damages jointly and severally against the defendants and pursuant to 17 U.S.C. § 504(c)(1) in an amount not less than \$30,000.00 for each violation of the United States Copyright Laws;
- C. That this Court award punitive damages jointly and severally against the defendants in an amount up to three times the amount of the damage award to RoyaltyStat;
- D. That this Court enter an Order temporarily and permanently enjoining the defendants from using, publishing, or selling any of the data, proprietary information, or trade secrets misappropriated from RoyaltyStat;
- E. That this Court award Plaintiff their costs of suit and their reasonable attorney's fees incurred pursuing this action; and
- F. Such other and further relief as this Court deems necessary and appropriate.

Dated: December 23, 2015

Respectfully Submitted,

/s/ Billy B. Ruhling, II

Billy B. Ruhling, II, Fed. Bar No. 17827

DIMUROGINSBERG PC

1101 King Street

Suite 610

Alexandria, VA 22314

Telephone: (703) 684-4333

Facsimile: (703) 548-3181

bruhling@dimuro.com

Counsel for Plaintiff RoyaltyStat LLC

Exhibit A: Pharmaceutical – Description Compare

Text from IntangibleSpring Database	RoyaltyStat Database Text	Company
Products related rotavirus vaccines for humans.	Exclusive patent and technical information license to make, have made, use, lease, sell, have sold and sublicense <u>products and processes related to rotavirus vaccines for humans.</u>	AVANT IMMUNOTHERAPEUTICS
Injectable vaccine containing the nonionic copolymer combined with fluvirina, a purified-surface-antigen influenza virus vaccine, to enhance the immune response in humans through Phase I human clinical trials.	Option to a co-exclusive patent, technology and know-how license to develop, manufacture, use, distribute and sell an <u>injectable vaccine containing the nonionic copolymer known as "CRL-1005" combined with fluvirina, a purified-surface-antigen influenza virus vaccine, to enhance the immune response in humans through Phase I human clinical trials.</u>	VAXCEL INC
Pharmaceutical formulations related to a recombinant Human Immunodeficiency Virus (HIV) surface glycoprotein gp 120 vaccine, for the prevention, but not treatment, of HIV infection and/or AIDS in humans.	Exclusive patent and know-how license to develop, make, have made, use, sell, and sublicense pharmaceutical formulations related to a recombinant <u>Human Immunodeficiency Virus (HIV) surface glycoprotein gp 120 vaccine, for the prevention, but not treatment, of HIV infection and/or AIDS in humans, with option for</u> <u>licensor to market and sell products.</u>	VAXGEN INCGenentech, Inc. / VaxGen, Inc.





Exhibit A: Pharmaceutical – Description Compare

TGF- β Factor formulations, antibodies, receptors, anitense molecules, pharmaceutical products, antagonists, vaccines and modulators.	Exclusive patent and technology cross-license with royalty-free know-how license to make, have made, use, import, market, offer, and sell the "GDF-8" TGF- β Factor formulations, antibodies, receptors, anitense molecules, pharmaceutical products, antagonists, vaccines and modulators	MetaMorphix Inc.
Biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell-based stem cells, cytokines, and viruses produced by mammalian cell culture techniques.	Purchase of rights related with patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell-based therapies, stem cells, cytokines, and viruses produced by mammalian cell culture techniques.	BIOVEST INTERNATIONAL INC Valens Offshore SPV II Corp. / Biovest International, Inc.
Pharmaceutical products consisting of DNA sequences obtained from the Per.C6 cells using licensee's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine.	Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceutical products consisting of DNA sequences obtained from the Per.C6 cells using licensee's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine.	Vascular Biogenics Ltd

Exhibit B: Semiconductor – Description Compare

Text from IntangibleSpring Database	RoyaltyStat Database Text	Company
Integrated circuits which include the Jazz PSA Platform, a logical hardware design for a general purpose, programmable microprocessor macro-architecture, Jazz VLIW microprocessors, computation units, and integration blocks, including the host bus interface, directed memory access controller, and external memory controllers.	Nonexclusive patent, technology and trademark license to design, have designed, manufacture, distribute and sell integrated circuits known as "INSECT PSA ICs," which include the Jazz PSA Platform, a logical hardware design for a general purpose, programmable microprocessor macro-architecture. Jazz VLIW microprocessors, computation units, and integration blocks, including the host bus interface, directed memory access controller, and external memory controllers.	QUICKLOGIC
Integrated circuits employing high performance CMOS processes on a silicon substrate having only an array of programmable logic cells consisting of basic gate and flip-flop elements interconnected by row and columns of programmable wiring channels.	Nonexclusive patent, copyrights and technology license to make, use, sell, lease and dispose of integrated circuits employing high performance CMOS processes on a silicon substrate having only an array of programmable logic cells consisting of basic gate and flip-flop elements interconnected by row and columns of programmable wiring channels.	QUICKLOGIC
Integrated circuits, chips, or chipsets using the mixed signal processor having a power output stage capable of amplifying only audio signals to a total output power of 25 watts or less per channel, when measured at 10% total harmonic distortion into a 4-ohm resistive load.	Nonexclusive patent and copyright license to make, have made, use, sell, offer and import integrated circuits, chips, or chipsets using the Mixed Signal Processor "MSP" core having a power output stage capable of amplifying only audio signals to a total output power of 25 watts or less per channel, when measured at 10% total harmonic distortion into a 4-ohm resistive load, and having significant additional functionality.	TRIPATH TECHNOLOGY INC
Membrane and filter manufacture and design for integrated circuits, semiconductors, semiconductor chips, microelectronics components, flat panel displays, solar cells, fiber optic cables, optical coatings, and coated optical fibers.	Option to exclusive patent license to make, have made, use, and sell products related to membrane manufacture, filter manufacture, and filter design, to companies that manufacture integrated circuits, semiconductors, semiconductor chips, microelectronics components, flat panel displays, solar cells, fiber optic cables, optical coatings, and coated optical fibers, as well as to integrated circuit IC and OEM equipment manufacturers, integrated circuit research laboratories, and to companies that manufacture, process and supply liquids, gases, and conductive materials.	MILLIPORE CORP /MA



LIBRARY OF CONGRESS

*Copyright Office
of the United States*

WASHINGTON, D.C.

THIS IS TO CERTIFY that on May 7, 2009 a claim to copyright a work identified as **ROYALTYSTAT WEBSITE ROYALTY TABLEAU** was registered under **TX 7-233-781**. This work was registered in accordance with provisions of the United States Copyright Law (Title 17 United States Code).

THIS IS TO CERTIFY FURTHER, that the attached is an additional certificate of this work.

IN WITNESS WHEREOF the seal of this Office is affixed hereto on November 20, 2015.

Maria A. Pallante
Register of Copyrights

Jarletta Walls

By: Jarletta Walls
Supervisory Copyright Specialist
Records Research and Certification Section
Office of Public Records and Repositories

Use of this material is governed by the U.S. copyright law 17 U.S.C. 101 et seq.

EXHIBIT

C

Certificate of Registration



This Certificate issued under the seal of the Copyright Office in accordance with title 17, *United States Code*, attests that registration has been made for the work identified below. The information on this certificate has been made a part of the Copyright Office records.

Maria A. Pallante

Register of Copyrights, United States of America

Registration Number
TX 7-233-781

Effective date of
registration:
May 7, 2009

Title _____

Title of Work: Royaltystat website royalty tableau

Completion/ Publication _____

Year of Completion: 2009

Date of 1st Publication: May 7, 2009

Nation of 1st Publication: United States

Author _____

Author: Royaltystat LLC

Author Created: text

Work made for hire: Yes

Citizen of: United States

Domiciled in: United States

Copyright claimant _____

Copyright Claimant: Royaltystat, LLC

5404 Blackistone Road, Bethesda, MD, 20816-1821, United States

Rights and Permissions _____

Organization Name: Royaltystat, LLC

Name: Ednaldo A. Silva

Email: esilva@royaltystat.com

Address: 5404 Blackistone Road

Bethesda, MD 20816-1821 United States

Certification _____

Name: Marcus G. Theodore, agent

Date: May 7, 2009

Correspondence: Yes

Registration #: TX0007233781

Service Request #: 1-190968612

Royaltystat, LLC
Ednaldo A. Silva
5404 Blackistone Road
Bethesda, MD 20816-1821 United States

LIBRARY OF CONGRESS

*Copyright Office
of the United States*

WASHINGTON, D.C.

THIS IS TO CERTIFY that the attached color photocopies are a true representation of the work entitled **ROYALTYSTAT WEBSITE ROYALTY TABLEAU** deposited in the Copyright Office with claim of copyright registered under number **TX 7-233-781**

THIS IS TO CERTIFY FURTHER, that due to the nature of the work deposited, the attached color photocopies are the best possible electrostatic positive prints available.


IN WITNESS WHEREOF, the seal of this Office is affixed hereto on November 20, 2015.

Maria A. Pallante
Register of Copyrights

Jarletta Walls

By: Jarletta Walls
Supervisory Copyright Specialist
Records Research and Certification Section
Office of Public Records and Repositories

Use of this material is governed by the U.S. law 17 U.S.C. 101 et seq.




of all right
ademarks
ection with
zal expect

tangible
to exclusi
Pharmaci
ind domai
nufacture,
iving oral

Delete F

1 Edit
Library



Royalty Rates for Licensing Intangibles

[Folders](#) [Search](#) [Edit Login](#) [Logoff](#)
[Create Invoice](#) [Library](#) [Contact](#)
[Saved Searches](#)

RoyaltyStat® On-Line 2834 - Patent Archive contains 9 agreement(s).

You have 818 agreements remaining on your limit of 1000 agreement(s).

[Statistics](#) [Go](#) [New Folder](#)
[Move Docs To](#) [Copy Docs To](#) [Go To](#)

2834 - Patent (9)





[Delete From Archive](#)


Sort Archive By: RoyaltyRate

Document/Agreement Details

Reference:	15516	Effective Date:	08/05/2007	Licensed Intangible
SIC Code:	2834	SEC Filing Date:	08/14/2008	Amendment to exclusive license to use "Gamma Pharmaceuticals"
SEC Filing:	Gamma Pharmaceuticals Inc	Royalty Rate:	1.50 %	trademarks and domain names to develop, manufacture, market and sell fast dissolving oral strips and oral gel.
SEC Filing:	10-Q PDF	Royalty Base:	Net Sales	
Agreement Type:	Trademark	Tiered Royalty:	Yes	
Licensor:	Jugular, Inc.			
Licensee:	Gamma Pharmaceuticals, Inc.			
Duration:	14 year(s)	Exclusive:	Exclusive	
Other Payments:				
Territory:	Worldwide			
Reference:	16627	Effective Date:	02/15/2005	Assignment of all rights, title, and interest in trademarks "Humbid,"
SIC Code:	2834	SEC Filing Date:	05/13/2005	used in connection with pharmaceutical expectorant products.
SEC Filing:	Adams Respiratory Therapeutics, Inc.	Royalty Rate:	2.00 %	
SEC Filing:	S-1/A PDF	Royalty Base:	Net Sales	
Agreement Type:	Trademark	Tiered Royalty:	Yes	
Licensor:	Cornerstone Biopharma, Inc.			
Licensee:	Adams Laboratories, Inc.			
Duration:	3 year(s)	Exclusive:	Unknown	

Other Payments:		Unknown		Exclusive license to use the "BioFIT" trademark to use, market, manufacture, sell and distribute herbal dietary supplements in tablet, 2-piece hard-shell and gelatin capsules delivery forms, including St. Johns Wort, Echinacea, Saw Palmetto, Ginseng and Ginkgo Biloba initially.	
Territory:					
Reference:	9655	Effective Date:	10/30/1998		
SIC Code:	2835	SEC Filed Date:	05/18/1999		
SEC Filing:	Paracelsian Inc /De/	Royalty Rate:	3.00 %		
SEC Filing:	10-KSB/A PDF	Royalty Base:	Net Sales		
Agreement Type:	Trademark	Tiered Royalty:	Yes		
Licensor:	Paracelsian, Inc.				
Licensee:	R.P. Scherer North America				
Duration:	1.5 Year(s)	Exclusive:	Exclusive		
Other Payments:	Milestone payments are \$50,000 for each of the 1st 5 customers to accept the initial products. Art. 6.1. New products milestone payments are \$50,000 for each new product upon acceptance by 2 customers. Art. 6.2.				
Territory:	Canada; Mexico; United States				
Reference:	255	Effective Date:	01/1993		Exclusive trademark license to promote, sell and sublicense prescription or over-the-counter pharmaceutical specialties containing Modafinil.
SIC Code:	2834	SEC Filed Date:	08/16/1999		
SEC Filing:	Cephalon Inc	Royalty Rate:	4.00 %		
SEC Filing:	10-Q PDF	Royalty Base:	Net Sales		
Agreement Type:	Trademark	Tiered Royalty:	Yes		
Licensor:	Genelco				
Licensee:	Cephalon, Inc.				
Duration:	99 year(s)	Exclusive:	Exclusive		
Other Payments:					
Territory:	Mexico; United States				
Reference:	15596	Effective Date:	07/21/1993		Amendment to exclusive trademark license.
SIC Code:	2834	SEC Filed Date:	08/16/1999		
SEC Filing:	Cephalon Inc	Royalty Rate:	4.00 %		
SEC Filing:	10-Q PDF	Royalty Base:	Net Sales		
Agreement Type:	Trademark	Tiered Royalty:	Yes		
Licensor:	Genelco SA				
Licensee:	Cephalon, Inc.				
Duration:	20 year(s)	Exclusive:	Exclusive		
Other Payments:					
Territory:	Europe				
Reference:	1949	Effective Date:	12/01/2000		Nonexclusive license to use the trademarks in connection with the
SIC Code:	2834	SEC Filed Date:	11/14/2000		

6		SEC Filing:	Carrington Laboratories Inc	Royalty Rate:	5.00 %	manufacture, marketing, advertisement, promotion and distribution of dermal management products under the trademarks Carrington, CarraGauze, CarraSorb, CarraCinamate, CarraFilm, SurgiSutures, CarraSmart, CarraDres, CarraColloid, CarraKlenz, UltraKlenz, MicroKlenz, CarraFoam, CarraWash, CarraFree, CarraScent, CarraFresh, CarraDerm, DiaB, and RadiaCare.
		Agreement Type:	10-Q PDF	Royalty Base:	Net Sales	
7		Licensors:	Carrington Laboratories, Inc.	Tiered Royalty:	Yes	Exclusive patent, technology and know-how license to use the "Donovex" trademark to import, store, distribute, use and sell products containing the pharmaceutical compound Calcipotriene, a vitamin D analogue with the formula C27H40O3 for human therapeutic use in the field of dermatology, with right to sublicense.
		Licensee:	Medline Industries, Inc.	Royalty Base:	Net Sales	
8		Duration:	5 year(s)	Exclusive:	Non-Exclusive	Exclusive patent license to promote, distribute, market, advertise, sell or offer the extended release ciprofloxacin HCl pharmaceutical product under the "Proquin XR" trademark.
		Other Payments:				
9		Territory:	Canada; Puerto Rico; United States; Virgin Islands			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Reference:	4660	Effective Date:	09/01/2005	
6		SIC Code:	2834	SEC Filing Date:	01/05/2004	Exclusive patent license to promote, distribute, market, advertise, sell or offer the extended release ciprofloxacin HCl pharmaceutical product under the "Proquin XR" trademark.
		SEC Filing:	Galen Holdings Plc	Royalty Rate:	10.00 %	
7		Agreement Type:	20-F/A PDF	Royalty Base:	Net Sales	Exclusive patent license to promote, distribute, market, advertise, sell or offer the extended release ciprofloxacin HCl pharmaceutical product under the "Proquin XR" trademark.
		Licensors:	Trademark	Tiered Royalty:	Yes	
8		Licensee:	Leo Pharma A/S			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Duration:	Galen (Chemicals) Ltd.	Exclusive:	Exclusive	
9		Other Payments:	20 year(s)			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Territory:	United States			
6		Reference:	8053	Effective Date:	07/21/2005	Exclusive patent license to promote, distribute, market, advertise, sell or offer the extended release ciprofloxacin HCl pharmaceutical product under the "Proquin XR" trademark.
		SIC Code:	2834	SEC Filing Date:	11/09/2005	
7		SEC Filing:	Depomed Inc	Royalty Rate:	25.00 %	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Agreement Type:	10-Q PDF	Royalty Base:	Net Sales	
8		Licensors:	Patent	Tiered Royalty:	Yes	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Licensee:	Trademark			
9		Duration:	Depomed Inc			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Other Payments:	Esprit Pharma Inc	Exclusive:	Exclusive	
6		Territory:	20 year(s)			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Reference:	United States			
7		SIC Code:	10711	Effective Date:	01/01/2007	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		SEC Filing:	2834	SEC Filing Date:	02/26/2007	
8		Agreement Type:	Auriga Laboratories, Inc.	Royalty Rate:	50.00 %	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Licensors:	Inc.	Royalty Base:	Net Sales	
9		Duration:	B-K PDF	Tiered Royalty:	Yes	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Other Payments:	Asset Purchase			
6		Territory:	Trademark			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Reference:				

	Licensors:	Auriga Laboratories, Inc.
	Licensees:	Athlon Pharmaceuticals, Inc.
	Duration:	Unknown
	Other Payments:	Unknown
	Territory:	Unknown

[Move Docs To](#) | [Copy Docs To](#) | [Go To](#)

[Statistics](#) | [Go](#) | [New Folder](#)

[Delete From Archive](#)

2834 - Patent (9)



[Subscribe](#) | [Royalty Rate Search](#) | [Library](#) | [Valuation](#)
[Intellectual Property](#) | [Intangible Assets](#) | [Royalty Rates](#)
[Contact Us](#) | [Home](#)

Copyright © RoyaltyStat LLC 04/17/2009
 Website by Woodbourne Solutions

**Receipt**

Copyright Office
Library of Congress
101 Independence Avenue SE
Washington DC 20559-6000



No. 1-1D86911

Date: 12/21/2015 13:08:54

Received

Form(s): TX (1)
Deposit Count: 1
Piece to Count: 1
Type of Deposit: text
Other Enclosures:
Title: RoyaltyStat Royalty Tableau
Additional Titles:
Priority:
of Documents:

Services

☐ Search Report
☐ Search
☐ Retrieval
☐ Correspondence
☐ Inspection
☐ Photocopies
☐ Additional Certificate
☐ Certification
☐ Secure Test Exam

Other:

Received From: RoyaltyStat LLC
5335 Wisconsin Avenue NW
Suite 920
Washington DC 20015

Phone: () -

Representing:

Phone: () -

Correspondence Id:**Fees**

No Fee: ☐
Fee to be Determined: ☐
Base Fee: \$85.00
Special Handling Fee: \$
Secure Test Exam Fee: \$
Total due: \$85.00

Method of Payment

Check:
Money Order:
Deposit Account:
Deposit Account Name:

Amount

Credit Card Auth # 24703G \$85.00 Visa

Total Payment: \$85.00


Notes:

Received By: RBRA

Receipt of material is merely a preliminary step in the registration and/or recordation process. It does not imply that any final determination has been made in the case, or that the material is acceptable for registration.

Official action on an application for copyright registration or a document for recordation can be taken only after there has been a full examination of the claim following regular Copyright Office procedures. We are glad to discuss questions involving copyright registration on the telephone or in person-to-person conversations. However, all statements made during these exploratory discussions must be considered provisional, and are not binding either upon the applicant or upon the Office.

This receipt acknowledges delivery of the material to the Copyright Office on the date indicated. When multiple claims are submitted by or on behalf of the same remitter, however, only one receipt will be provided. If you are submitting multiple claims, only one title will appear on the receipt.



Copyright Office has not been subject to copyright. For certain laws, check the Copyright Office website at www.copyright.gov with the Copyright Office, or call (202) 707-4000.

Form TX
For a Nondramatic Literary Work
UNITED STATES COPYRIGHT OFFICE
REGISTRATION NUMBER

Privacy Act Notice: Sections 408-410 of title 17 of the United States Code authorize the Copyright Office to collect the personally identifying information requested on this form in order to process the application for copyright registration. By providing this information you are agreeing to routine uses of the information that include publication to give legal notice of your copyright claim as required by 17 U.S.C. §705. It will appear in the Office's online catalog. If you do not provide the information requested, registration may be refused or delayed, and you may not be entitled to certain relief, remedies, and benefits under the copyright law.

TX TXU
EFFECTIVE DATE OF REGISTRATION

Month Day Year

DO NOT WRITE ABOVE THIS LINE. IF YOU NEED MORE SPACE, USE A SEPARATE CONTINUATION SHEET.

TITLE OF THIS WORK ▼

RoyaltyStat Royalty Tableau

PREVIOUS OR ALTERNATIVE TITLES ▼

PUBLICATION AS A CONTRIBUTION If this work was published as a contribution to a periodical, serial, or collection, give information about the collective work in which the contribution appeared. Title of Collective Work ▼

If published in a periodical or serial give: Volume ▼ Number ▼ Issue Date ▼ On Pages ▼

NAME OF AUTHOR ▼

RoyaltyStat, LLC

DATES OF BIRTH AND DEATH
Year Born ▼ Year Died ▼

Was this contribution to the work a "work made for hire"?
☒ Yes
☐ No

AUTHOR'S NATIONALITY OR DOMICILE
Name of Country
OR { Citizen of United States
Domiciled in _____

WAS THIS AUTHOR'S CONTRIBUTION TO THE WORK
Anonymous? ☐ Yes ☒ No
Pseudonymous? ☐ Yes ☒ No
If the answer to either of these questions is "Yes," see detailed instructions.

NATURE OF AUTHORSHIP Briefly describe nature of material created by this author in which copyright is claimed. ▼

Selection, coordination and arrangement in material and data; original text, material and data.

NAME OF AUTHOR ▼

DATES OF BIRTH AND DEATH
Year Born ▼ Year Died ▼

Was this contribution to the work a "work made for hire"?
☐ Yes
☐ No

AUTHOR'S NATIONALITY OR DOMICILE
Name of Country
OR { Citizen of _____
Domiciled in _____

WAS THIS AUTHOR'S CONTRIBUTION TO THE WORK
Anonymous? ☐ Yes ☐ No
Pseudonymous? ☐ Yes ☐ No
If the answer to either of these questions is "Yes," see detailed instructions.

NATURE OF AUTHORSHIP Briefly describe nature of material created by this author in which copyright is claimed. ▼

NAME OF AUTHOR ▼

DATES OF BIRTH AND DEATH
Year Born ▼ Year Died ▼

Was this contribution to the work a "work made for hire"?
☐ Yes
☐ No

AUTHOR'S NATIONALITY OR DOMICILE
Name of Country
OR { Citizen of _____
Domiciled in _____

WAS THIS AUTHOR'S CONTRIBUTION TO THE WORK
Anonymous? ☐ Yes ☐ No
Pseudonymous? ☐ Yes ☐ No
If the answer to either of these questions is "Yes," see detailed instructions.

NATURE OF AUTHORSHIP Briefly describe nature of material created by this author in which copyright is claimed. ▼

YEAR IN WHICH CREATION OF THIS WORK WAS COMPLETED This information must be given in all cases.
2015 Year

DATE AND NATION OF FIRST PUBLICATION OF THIS PARTICULAR WORK Complete this information ONLY if this work has been published.
Month November Day 20 Year 2015 Nation

COPYRIGHT CLAIMANT(S) Name and address must be given even if the claimant is the same as the author given in space 2. ▼

RoyaltyStat, LLC, 5335 Wisconsin Ave., N.W., Suite 920, Washington, D.C. 20015-2084

TRANSFER If the claimant(s) named here in space 4 is (are) different from the author(s) named in space 2, give a brief statement of how the claimant(s) obtained ownership of the copyright. ▼

APPLICATION RECEIVED

ONE DEPOSIT RECEIVED

TWO DEPOSITS RECEIVED

FUNDS RECEIVED

MORE ON BACK ▶

• Complete all applicable spaces (numbers 5-9) on the reverse side of this page.
• See detailed instructions.
• Sign the form at line 8.

DO NOT WRITE HERE

Page 1 of _____ pages.

NOTE

Under the law, the "author" of a "work made for hire" is generally the employer, not the employee (see instructions). For any part of this work that was "made for hire" check "Yes" in the space provided, give the employer (or other person for whom the work was prepared) as "Author" of that part, and leave the space for dates of birth and death blank.

See instructions before completing this space.

EXAMINED BY

FORM TX

CHECKED BY

☐ CORRESPONDENCE
Yes
FOR
COPYRIGHT
OFFICE
USE
ONLY

DO NOT WRITE ABOVE THIS LINE. IF YOU NEED MORE SPACE, USE A SEPARATE CONTINUATION SHEET.

PREVIOUS REGISTRATION Has registration for this work, or for an earlier version of this work, already been made in the Copyright Office?

☒ Yes ☐ No If your answer is "Yes," why is another registration being sought? (Check appropriate box.) ▼a. ☐ This is the first published edition of a work previously registered in unpublished form.b. ☐ This is the first application submitted by this author as copyright claimant.c. ☐ This is a changed version of the work, as shown by space 6 on this application.

If your answer is "Yes," give: Previous Registration Number ▶ TX0007233781

Year of Registration ▶ 2009

DERIVATIVE WORK OR COMPILATION

Preexisting Material Identify any preexisting work or works that this work is based on or incorporates. ▼

Material Added to This Work Give a brief, general statement of the material that has been added to this work and in which copyright is claimed. ▼

Registrant continued to add material and data of the same nature as that included in the previously registered work.

DEPOSIT ACCOUNT If the registration fee is to be charged to a deposit account established in the Copyright Office, give name and number of account.

Name ▼

Account Number ▼

CORRESPONDENCE Give name and address to which correspondence about this application should be sent. Name/Address/Apt/City/State/Zip ▼

Cecil E. Key, DiMuroGinsberg P.C., 1101 King Street, Suite 610, Alexandria, Virginia, 22314

Area code and daytime telephone number ▶ (703) 684-4333

Fax number ▶ (703) 548-3181

Email ▶ ckey@dimuro.com

CERTIFICATION* I, the undersigned, hereby certify that I am the

Check only one ▶

☐ author☐ other copyright claimant☐ owner of exclusive right(s)☒ authorized agent of RoyaltyStat, LLC

of the work identified in this application and that the statements made by me in this application are correct to the best of my knowledge.

Name of author or other copyright claimant, or owner of exclusive right(s) ▲

Typed or printed name and date ▼ If this application gives a date of publication in space 3, do not sign and submit it before that date.

Cecil E. Key

Date ▶ December 21, 2015

Handwritten signature ▼

Certificate
will be
mailed in
window
envelope
to this
address:

Name ▼

Number/Street/Apt ▼

City/State/Zip ▼

YOU MUST:

- Complete all necessary spaces
- Sign your application in space 8.

SEND ALL 3 ELEMENTS
(IN THE SAME PACKAGE):

1. Application form
2. Nonrefundable filing fee in check or money order payable to Registrar of Copyrights
3. Deposit material

MAIL TO:

Library of Congress
Copyright Office-TX
101 Independence Avenue SE
Washington, DC 20559

*17 U.S.C. §506(e): Any person who knowingly makes a false representation of a material fact in the application for copyright registration provided for by section 409, or in any written statement filed in connection with the application, shall be fined not more than \$2,500.


[DATABASE](#) | [ADMIN](#) | [CONTACT](#) | [LOG OFF](#)
[DASHBOARD](#) | [SEARCH](#) | [MY ACCOUNT](#) | [FEATURES](#)

Folder: Copyrights (50) - RoyaltyTableau™

Royalty Tableau		Net Sales % (50)	All Agreements	Filter Data	Folder	Export to
<div><div></div></div>						
ID	REF		TRANSLATE	ROYALTY RATE		
1.	31130	Aegis Therapeutics, LLC / LightLuxe Therapeutics, Inc.	Exclusive option for exclusive patent, know-how, process and trademark license to research, develop, make, have made, use, sell, offer, import, export, commercialize, export and sublicense pharmaceutical formulations containing nifedipine using the 'Intravall' delivery agents... More	5.00 %	Net Sales	Know-how, Option, Patent, Process, Research, Supply, Technology, Trademark
2.	31128	The Penn State Research Foundation / Inovio Pharmaceuticals, Inc.	Exclusive patent and know-how license to make, have made, use, lease, sell, practice, have practiced and sublicense products and processes related to oploid growth factor, taxanes, and gemcitabine to treat cancer, for all human uses in the field of oncology and to treat hep... More	10.00 %	Net Sales	Know-how, Patent, Process
3.	31122	SensorMedics Corp. a/k/a CareFusion / Advanced Inhalation Therapies (AIT) Ltd.	Nonexclusive patent license to develop, make, have made, use, have used, sell, offer, have sold and import products, services and delivery devices using nitric oxide and nitric oxide therapy to treat diseases or conditions in humans, excluding veterinary applications.	5.00 %	Net Sales	Patent
4.	31036	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and sublicense non-prescription OTC products containing a serot... More	6.00 %	Net Sales	Know-how, Patent, Process, Technology
5.	31034	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and sublicense prescription products containing a serotonin typ... More	20.00 %	Net Sales	Know-how, Patent, Process, Technology
6.	31031	Renovis, Inc. / Pfizer Inc.	Exclusive patent, know-how and technology license to manufacture, use, sell, offer, import and sublicense VR-1 antagonists, either as a single agent or in combination, to treat human diseases or disorders, including neuropathic pain, chronic pain, headache, bladder, colon an... More	12.00 %	Net Sales	Know-how, Patent, Technology
7.	31035	ChemoCentryx, Inc. / Glaxo Group Ltd.	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug candidate compounds that target chemokine receptors, to treat o... More	18.00 %	Net Sales	Know-how, Option, Patent, Research, Technology
8.	31072	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and sublicense prescription products containing a serotonin typ... More	25.00 %	Net Sales	Know-how, Patent, Process, Technology
9.	31047	ChemoCentryx, Inc. / Glaxo Group Ltd.	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug candidate compounds that target chemokine receptors, to treat o... More	22.00 %	Net Sales	Know-how, Option, Patent, Research, Technology
10.	31038	Midatech Ltd.; MonoSol Rx, LLC / MonoSol Rx, LLC; Midatech Ltd.	Collaborative development to integrate nanoparticles and self-dissolving oral thin film technologies, with exclusive patent, know-how, process and technology cross-licenses to develop, manufacture, commercialize and sublicense pharmaceutical products to prevent and treat dis... More	10.00 %	Net Sales	Cross-License, Know-how, Patent, Process, Research, Technology

11.	30372	Cornell University, represented by the Cornell Center for Technology Enterprise and Commercialization / BioPancreate, Inc.	Exclusive patent, process and technology license to make, have made, use, have used, sell, have sold, offer, have offered, import, have imported and sublicense products related to commensal bacteria as signal mediators and bacterial conversion of intestinal cells to insulin... More	2.50 %	Net Sales	Patent, Process, Technology	Worldwide
12.	30347	Comvita New Zealand Ltd. / Dermia Sciences, Inc.	Patent and know-how license to use the "Medihoney" trademarks to make, use, import, offer, supply, sell, lease, distribute, promote and sublicense products that contain medical honey to treat, mitigate or prevent human disease, including dermal soars, acute and chronic wound... More	11.00 %	Net Sales	Know-how, Patent, Trademark	Worldwide
13.	30391	Yissum Research Development Co. of the Hebrew University of Jerusalem / Intec Pharmaceutical Partnership Ltd.	Exclusive patent, know-how and technology license to develop, manufacture, market and sublicense products related to a biodegradable system retained in the stomach to expand the therapeutic potential of drugs having a narrow absorption window.	3.00 %	Net Sales	Know-how, Patent, Research, Technology	Unknown
14.	30430	Onconova Therapeutics, Inc. / SymBio Pharmaceuticals Ltd.	Exclusive patent, know-how and process license to develop, manufacture, use, sell, offer, import, market, distribute, promote and sublicense pharmaceutical preparations for human use which contain an oncology compound, in oral and injectable formulations, to treat, ameliorat... More	20.00 %	Net Sales	Know-how, Patent, Process, Supply	Japan, Korea, Republic of
15.	30153	The General Hospital Corp. d/b/a Massachusetts General Hospital / Vxcell Endocrine Science, Inc., a subsidiary of VxCell, Inc.	Exclusive patent, know-how, process and technical information license to make, have made, use, sell, offer, import and sublicense products related to pancreatic stem cells for transplantation or to treat diabetes, to diagnose, treat or prevent human and animal diseases and c... More	2.00 %	Net Sales	Know-how, Patent, Process, Technology	Worldwide
16.	30346	HegeneHx Biopharmaceuticals, Inc. / DeLiazo Farmaceutica Ltda	Exclusive patent, know-how, process and technology license to use, produce, have produced, sell and sublicense prescription or over-the-counter pharmaceutical products and medical devices containing the Thymosin Beta 4 amino acid peptide, to treat any indication for external... More	3.75 %	Net Sales	Know-how, Patent, Process, Supply, Technology, Trademark	Albania, Armenia, Austria, Azerbaijan, Belgium, Bolivia, Brazil
17.	30198	Atkermes, Inc., licensee of The Children's Hospital Research Foundation and Children's Hospital, Inc. / Targeted Genetics Corp.	Exclusive patent and technology sublicense to make, have made, use, lease, have sold, sell and sublicense products which utilize the C12 adeno-associated virus cell-line to treat and prevent pulmonary disease, infectious diseases, tumors, cardiovascular disorders, metabolic... More	6.00 %	Net Sales	Patent, Sublicense, Technology	Worldwide
18.	30392	Senetek PLC / Ardana Bioscience Ltd.	Exclusive patent, copyright, proprietary information, process and trademark license to use, manufacture, market, sell, distribute and sublicense a pharmaceutical product for the local treatment of erectile dysfunction containing vasoactive intestinal polypeptide and phenol... More	12.00 %	Net Sales	Copyrights, Patent, Process, Proprietary Info, Trademark	Canada, United States
19.	30398	Senetek PLC / Ardana Bioscience Ltd.	Exclusive patent, copyright, proprietary information, process and trademark license to use, manufacture, market, sell, distribute and sublicense a pharmaceutical product for the local treatment of erectile dysfunction containing vasoactive intestinal polypeptide and phenol... More	10.00 %	Net Sales	Copyrights, Patent, Process, Proprietary Info, Trademark	Europe
20.	30474	Crucell Holland BV / Vascular Biogenics Ltd.	Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceutical products consisting of DNA sequences obtained from the PerCB cells using licensee's vascular targeting system platform in combination with the gen... More	2.00 %	Net Sales	Know-how, Patent, Process	Worldwide
21.	30470	Tel Hashomer - Medical Research, Infrastructure and Services Ltd. / Vascular Biogenics Ltd.; Dror Harari	Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark license to develop, manufacture, sell, market and sublicense products and devices related to enhancing targeting of viral vectors, expression of a gene-of-interest in cells, treatment... More	1.00 %	Net Sales	Copyrights, Know-how, Patent, Process, Trade Name, Trademark	Worldwide
22.	30342	DOP LLC / ZS Pharma, Inc.	Exclusive patent, process and technology license to practice, research, develop, make, have made, use, sell, have sold, offer, import, export, market, commercialize, exploit and sublicense products for removing toxins from bodily fluids and the gastrointestinal tract of huma... More	5.00 %	Net Sales	Patent, Process, Technology	Worldwide
23.	30128	University of Massachusetts / Amaranthus Bioscience Holdings, Inc.	Exclusive patent license to develop, have developed, make, have made, use, have used, import, have imported, sell, have sold, and sublicense products and services related to soluble MANF in pancreatic beta-cell disorders, for all fields except commercial sale of research rea... More	2.00 %	Net Sales	Patent	Worldwide
24.	30381	Yada Research and Development Co. Ltd. / XTL Biopharmaceuticals Ltd.	Exclusive patent and know-how license to research, develop, manufacture, market, sell and sublicense products containing a synthetic peptide to diagnose, prevent or treat systemic lupus erythematosus or other clinical indications.	3.00 %	Net Sales	Know-how, Patent	Worldwide

25.	27108	CIMA Labs Inc. / Schwarz Pharma, Inc.	Exclusive patent, know-how, and technology license to use the "CIMA," "DuraSolv," "PakSolv," "DraSolv" and "Meltabs" trademarks to market, distribute, sell and sublicense pharmaceutical prescription products containing metoprolol HCl, carbidepallevodopa, bado/en, alprazolam. More	6.00 %	Net Sales	Know-how, Patent, Supply, Technology	Canada, Mexico, Puerto Rico, United States, ... More
26.	27581	Santarus, Inc. / Glaxo Group Ltd.	Exclusive patent, know-how and process license to sell, offer, import and sublicense pharmaceutical products incorporating omeprazole in combination with buffering agents, as capsules, powder for oral suspension or chewable tablets, for all human therapeutic indications, for... More	27.50 %	Net Sales	Know-how, Patent, Process	Afghanistan, Algeria, Argentina, Bahrain, Belize, ... More
27.	27630	Oklahoma Medical Research Foundation; The University of Kentucky Research Foundation / Centaur Pharmaceuticals, Inc.	Exclusive patent, know-how, process and technology license to make, have made, use, lease, practice, sell and sublicense products related to spin-trapping compounds and phenylbutyl compositions, to treat: oxidative tissue damage, prevent gastric ulceration, and inhibit aging.	3.00 %	Net Sales	Know-how, Patent, Process, Technology	Worldwide
28.	27659	Vanderbilt University / NephroGenex, Inc.	Exclusive patent and process license to make, have made, use, sell, offer, import and sublicense products for therapeutic application of pyridoxamine in acute renal failure and other critical illnesses where the occurrence of increased oxidative stress and elevated levels of... More	3.00 %	Net Sales	Patent, Process	Worldwide
29.	27521	Fresh Start Private Management, Inc.; licensee of Trinity Rx Solutions / JPL, LLC	Exclusive patent, know-how, process, copyrights and trademarks sublicense to obtain, market, use, sell, and offer Naltrexone implants to treat alcoholism, and to operate a related alcohol rehabilitation counseling program.	10.00 %	Net Sales	Copyrights, Know-how, Patent, Process, Sublicense, Trademark	United States
30.	27179	Canterbury Laboratories, LLC, successor-in-interest to Hygeia Therapeutics, licensee of Yale University / Femdale Pharma Group, Inc.	Exclusive patent sublicense to manufacture, have manufactured, use, market, have marketed, sell, have sold, import, export and sublicense non-prescription products for topical administration related to carboxylic acid esters as locally active estrogen, for direct sales to... More	10.30 %	Net Sales	Patent, Sublicense	Worldwide
31.	27040	Haven Biotechnologies, Inc. / ImmunoGen, Inc.	Collaborative research program, with exclusive patent and know-how license to develop, make, have made, use, sell, offer, have sold, import, have imported and sublicense pharmaceutical products to treat cancer in humans containing a monoclonal antibody generated and screened... More	5.50 %	Net Sales	Know-how, Patent, Research	Canada, Europe, Mexico, United States
32.	25913	Haven Biotechnologies, Inc. / ImmunoGen, Inc.	Collaborative research program, with exclusive patent and know-how license to develop, make, have made, use, sell, offer, have sold, import, have imported and sublicense pharmaceutical products to treat cancer in humans containing a monoclonal antibody generated and screened... More	9.50 %	Net Sales	Know-how, Patent, Research	Canada, Europe, Mexico, United States
33.	22106	Dr. Falk Pharma GmbH / Coronado Biosciences, Inc.	Framework of terms for collaboration agreement with exclusive patent and know-how license to develop, use, have made, commercialize and sell pharmaceutical compositions containing Trichuris suis ova in any formulation or delivery system, with further development of the product... More	1.00 %	Net Sales	Know-how, Patent	Japan, North America, South America
34.	10042	Rutgers, The State University of New Jersey / Xenogenics Corp.	Exclusive patent and process license to make, have made, use, import, put into use, distribute, sell, have sold and sublicense products related to a bioabsorbable stent for interventional cardiology and peripheral vascular applications.	3.00 %	Net Sales	Patent, Process	Worldwide
35.	10320	PDL BioPharma, Inc. / Alexion Pharmaceuticals, Inc.	Stipulation agreement to manufacture, use, offer, sell and import patented products related to the "Soliris" humanized antibody product to treat paroxysmal nocturnal hemoglobinuria.	4.00 %	Net Sales	Liabilities, Patent	Unknown
36.	17058	Schering Aktiengesellschaft / Exhale Therapeutics, Inc.	Exclusive patent, know-how, process and trademark license to develop, commercialize, use, market, sell, import, distribute and sublicense pharmaceutical products containing iloprost, trometamol for inhaled use, for pulmonary hypertension in humans, with licensor to manufacture... More	20.00 %	Net Sales	Know-how, Patent, Process, Supply, Trademark	United States
37.	17557	Board of Regents of The University of Texas System, on behalf of The University of Texas M. D. Anderson Cancer Center / Calisto Pharmaceuticals, Inc.	Exclusive patent and technology license to manufacture, have manufactured, use, import, offer, sell and sublicense unspecified products for use in human or animal therapeutics, with exclusive option to improvements based on activity or structure of Tyrosinase.	5.00 %	Net Sales	Option, Patent, Technology	Worldwide
38.	17655	Receptors LLC / VeriChip Corp.	Exclusive patent and technology license to make, have made, sell, have sold, offer, import, export and sublicense products and services for the detection and sub-type identification of the Influenza virus using the "CARA" artificial receptor, synthetic competitor agent, and ... More	50.00 %	Net Sales	Patent, Technology	Worldwide

Statistical Interval

Statistical Interval



Folder: Cecil (14) - RoyaltyTableau™

DASHBOARD SEARCH ACCOUNT FEATURES

Royalty Tableau		Net Sales % (14)	All Agreements	Filter Data	Folder	Download		
REF	EFFECTIVE DATE			TRANSLATE	ROYALTY RATE			
1. 28471	4/15/2011	20	Cruell Holland BV / Vascular Biogenics Ltd.	Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceutical products consisting of DNA sequences obtained from the FecC5 cells using licensees's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine.	2.00 %	Net Sales	No	Know-how, Patent Process
Reason:								
2. 28470	02/03/2013	20	Tel Hashomer - Medical Research, Infrastructure and Services Ltd. / Vascular Biogenics Ltd., Dior Hérats	Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark license to develop, manufacture, sell, market and sublicense products and devices related to enhancing targeting of viral vectors' expression at a gene-of-interest in cells, treatment. More	1.00 %	Net Sales	No	Copyrights, Know-how, Patent Process, Trade Name, Trademark
Reason:								
3. 15310	08/10/2009	5	Gruppo Santorigi, LLC / Eternal Image	Exclusive sublicense to use the "Vatican Observatory" trade name and logo to design, manufacture, sell, distribute and advertise religious themed products for funerary use, including urns, cremation keepsakes, caskets, casket yells, burial vaults, burial niches, columbariums, monuments and markers, prayer cards, guest signature books, and candles.	10.00 %	Net Sales	No	Sublicense, Trade Name
Reason:								
4. 16244	8/4/1995	15	Vaxcel, Inc. / Connaught Laboratories, Inc.	Exclusive patent, technology and know-how, license to manufacture, market and sublicense a parenteral injectable vaccine containing the polyoxyethylene/polyoxypropylene copolymer adjuvant known as "CRL-1005" combined with recombinant lipoplated outer surface protein A "OspA" from <i>Escherichia coli</i> .	8.00 % 6.00 %	Net Sales	Yes	Patent, Research, Technology
Reason:								
5. 16233	10/13/1995	2	Vaxcel, Inc. / Medeva Europe Ltd.	Option to a co-exclusive patent, technology and know-how license to develop, manufacture, use, distribute and sell an injectable vaccine containing the nonionic copolymer known as "CRL-1005" combined with influenza, a purified surface-antigen influenza virus vaccine, to enhance the immune response in humans through Phase I human clinical trials.	10.00 % 6.00 %	Net Sales	Yes	Option, Patent, Research
Reason:								
6. 15930	1/31/2007	2.9	The Cat Fanciers Association, Inc. / Eternal Image, Inc.	Nonexclusive license to use the "The Cat Fanciers Association" trademarks, copyrights, and designs to manufacture, distribute, promote and sell a funerary line of branded urns, through	6.00 %	Net Sales	No	Copyrights, Trademark
Reason:								

7.	15928	11/14/2005	3.1	The American Kennel Club / Eternal Image, LLC	Nonexclusive license to use the "The American Kennel Club" trademarks and copyrights to manufacture, distribute, promote and sell a funerary line of AKC branded urns, through pet store chains, mass retailers and Internet.	10.00 %	Net Sales	Yes	Copyrights, Trademark
	Reason:								
8.	15927	Unknown	Unknown	Collegiate Licensing Co. / Eternal Image Inc.	Nonexclusive license to use the Louisiana State University name, trademarks, and indicia to manufacture, advertise, distribute and sell memorial products such as caskets, urns, and vaults.	8.00 %	Net Sales	Yes	Copyrights, Trademark
	Reason:								
9.	16906	6/23/2007	3.33	CBS Consumer Products, a division of CBS Broadcasting Inc. / Eternal Image	Nonexclusive copyright license to use the "Star Trek" trademark to distribute, promote, manufacture and sell caskets, urns, monuments and vaults to funeral homes.	10.00 %	Net Sales	Yes	Copyrights, Trademark
	Reason:								
10.	15925	01/01/2007	2	Major League Baseball Properties, Inc. / Eternal Image Inc.	Amendment to nonexclusive license to use the American and National Leagues, Major League Baseball, and individual baseball clubs' trademarks, copyrights, and logos to manufacture, distribute, promote, advertise and sell caskets, urns, headstones and vault covers made of comp... More	12.00 %	Net Sales	No	Amendment, Copyrights, Trademark
	Reason:								
11.	15020	5/30/2009	Unknown	Valens Offshore SPV II, Corp. / Biovest International, Inc.	Amendment to royalty agreement for patented biologic products to extend maturity date of promissory note.	9.46 % 5.96 %	Net Sales	Yes	Amendment, Pat
	Reason:								
12.	14929	12/10/2007	Perpetual	Valens Offshore SPV II Corp. / Biovest International, Inc.	Purchase of rights related with patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell-based therapies, stem cells, cy... More	2.12 %	Net Sales	No	Asset Purchase, Patent
	Reason:								
13.	14928	12/10/2007	Perpetual	Valens U.S. SPV I, LLC / Biovest International, Inc.	Agreement pursuant to a Note Purchase to provide a royalty for patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell... More	2.88 %	Net Sales	No	Patent
	Reason:								
14.	13775	10/14/2002	20	MetaMorphix, Inc. / Wyeth f/k/a American Home Products Corp. through Genetics Institute, L.L.C. f/k/a Genetics Institute, Inc.	Exclusive patent and technology cross-license with royalty-free know-how license to make, have made, use, import, market, offer, and sell the "GDF-8" TGF-B Factor formulations, antibodies, receptors, antisense molecules, pharmaceutical products, antagonists, vaccines and mo... More	2.00 %	Net Sales	No	Cross-License, Know-how, Patent Technology
	Reason:								

Unfiltered	14	1.00	2.09	8.00	6.82	7.02	10.00	3.89	12.00
Filtered	14	1.00	2.09	8.00	6.82	7.02	10.00	3.89	12.00
Statistical Interval									



ROYALTYSTAT®

DATABASE | ADMIN | CONTACT | LOG OFF

DASHBOARD | SEARCH | MY ACCOUNT | FEATURES ▾

Folder: Cecil (14) - RoyaltyTableau™ ⓘ

Royalty Tableau	Net Sales % (14)	All Agreements	Filter Data	Folder	Download				
TRANSLATE ROYALTY RATE									
onexclusive patent, know-how and process ense to develop, use, import, manufacture; ave made, offer and sell pharmaceutical roducts consisting of DNA sequences obtained om the Per.C6 cells using licensee's vascular rgeting system platform in combination with the nzyme of a serotype 5 human adenovirus, to eat cancer in humans using an adenoviral actor, including therapeutic gene sequences, ut not serving as a vaccine.	2.00 %	Net Sales	No	Know-how, Patent, Process	Pharmaceutical & Biotech	2834	325412	License Fee, Milestone Payment	Worldwide
ettlement of dispute, with patent, know-how, rocess, copyrights, trade names and trademark ense to develop, manufacture, sell, market and ublicense products and devices related to hancing targeting of viral vectors, expression f a gene-of-interest in cells, treatment... More	1.00 %	Net Sales	No	Copyrights, Know- how, Patent, Process, Trade Name, Trademark	Pharmaceutical & Biotech	2834	325412	Sublicense Royalty	Worldwide
clusive sublicense to use the "Vatican bservatory" trade name and logo to design, anufacture, sell, distribute and advertise iligious themed products for funerary use, cluding urns, cremation keepsakes, caskets, asket veils, burial vaults, burial niches, plumbartums, monuments and markers, prayer rds, guest signature books, and candles.	10.00 %	Net Sales	No	Sublicense, Trade Name	Consumer Products	3990		Minimum Royalty, Sublicense Royalty	Worldwide with Exceptions
clusive patent, technology and know-how ense to manufacture, market and sublicense a reteral injectable vaccine containing the glyoxyethylene/polyoxypropylene copolymer djuvant known as "CRL-1005" combined with combinant lipidated outer surface protein A CspA" L... More	8.00 % 6.00 %	Net Sales	Yes	Patent, Research, Technology	Pharmaceutical & Biotech	2836	325414	Milestone Payment, Other Payments	Worldwide
ption to a co-exclusive patent, technology and ow-how license to develop, manufacture, use, tribute and sell an injectable vaccine ntaining the hononib copolymer known as CRL-1005" combined with fluvirina, a purified- urface-antigen influenza virus vaccine, to hance the immune response in humans rough Phase I human clinical trials.	10.00 % 6.00 %	Net Sales	Yes	Option, Patent, Research	Pharmaceutical & Biotech	2836	325414	Upfront Payment, Other Payments	Unknown
ontexclusive license to use the "The Cat nciers' Association" trademarks, copyrights, rd designs to manufacture, distribute, promote rd sell a funerary line of branded urns, though ase retailers and funeral homes.	8.00 %	Net Sales	No	Copyrights, Trademark	Consumer Products	3990		Upfront Payment, Minimum Royalty	Canada, United States

exclusive license to use the "The American Rel Club" trademarks and copyrights to: manufacture, distribute, promote and sell a variety line of AKC branded urns, through pet chains, mass retailers and internet.	10.00 %	Net Sales	Yes	Copyrights, Trademark	Consumer Products	3990	Upfront Payment, Minimum Royalty	Canada, United States
exclusive license to use the Louisiana State University name, trademarks, and indicia to manufacture, advertise, distribute and sell promotional products such as caskets, urns, and etc.	8.00 %	Net Sales	Yes	Copyrights, Trademark	Consumer Products	3990		United States
exclusive copyright license to use the "Star " trademark to distribute, promote, manufacture and sell caskets, urns, monuments vaults to funeral homes.	10.00 %	Net Sales	Yes	Copyrights, Trademark	Consumer Products, Broadcasting	3990	Upfront Payment	Australia, Canada, Europe, Japan, New Zealand, United... More
amendment to nonexclusive license to use the American and National Leagues, Major League Baseball, and individual baseball clubs' trademarks, copyrights, and logos to manufacture, distribute, promote, advertise and caskets, urns, headstones and vault covers etc of comp... More	12.00 %	Net Sales	No	Amendment, Copyrights, Trademark	Advertising	3990		United States
amendment to royalty agreement for patented biologic products to extend maturity date of royalty note,	9.46 % 5.96 %	Net Sales	Yes	Amendment, Patent	Pharmaceutical & Biotech	2834 325412		Unknown
license of rights related with patented pharmaceutical products, including: monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma renal cell carcinoma; cell-based therapies, stem cells, etc... More	2.12 %	Net Sales	No	Asset Purchase, Patent	Pharmaceutical & Biotech	2834 325412		Worldwide
amendment pursuant to a Note Purchase to provide a royalty for patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as non-Hodgkins lymphoma and renal cell carcinoma, cell... More	2.88 %	Net Sales	No	Patent	Pharmaceutical & Biotech	2834 325412		Worldwide
exclusive patent and technology cross-license royalty-free know-how license to make, have, use, import, market, offer, and sell the F-8r TGF-B Factor formulations, antibodies, proteins, antisense molecules, pharmaceutical products, antagonists, vaccines and mo... More	2.00 %	Net Sales	No	Cross-License, Know-how, Patent, Technology	Pharmaceutical & Biotech	2834 325412		Unknown

Unfiltered	14	1.00	2.09	8.00	6.82	7.02	10.00	3.89	12.00
Filtered	14	1.00	2.09	8.00	6.82	7.02	10.00	3.89	12.00
Statistical Interval									


[DATABASE](#) | [ADMIN](#) | [CONTACT](#) | [Log out](#)
[DASHBOARD](#) | [SEARCH](#) | [MY ACCOUNT](#) ▾ | [FEATURES](#) ▾

Search Results Custom ?

Industry:	Pharmaceutical & Biotech	Refine Search	(3983 Hits)
Sub-Industry:	Gastro Intestinal		(123 Hits)
Agreement Type:	Patent	Refine Search	(107 Hits)
Agreement Type Excluding:	Franchise, Asset Purchase, Amendment	Refine Search	(83 Hits)
Royalty Base:	Net Sales	Refine Search	(79 Hits)
Related Parties:	Exclude		(76 Hits)

[Delete All](#) [Save All](#) [Export](#) [Print](#) [Save to New Folder](#)

We found 76 agreements matching your search criteria.

1	31128	2836	The Penn State Research Foundation / Innoviva Pharmaceuticals, Inc.	2005	20	Exclusive patent and know-how license to make, have made, use, lease, sell, practice, have practiced and sublicense products and processes related to opioid growth factor, taxanes, and gemcitabine to treat cancer, f... More	10.00 %	Net Sales	Copyrights
2	31096	2834	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and... More	8.00 %	Net Sales	Copyrights
3	31094	2834	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and... More	20.00 %	Net Sales	Copyrights
4	31091	2834	Renovis, Inc. / Pfizer Inc.	2005	20	Exclusive patent, know-how and technology license to manufacture, use, sell, offer, import and sublicense VEGF antagonists, either as a single agent or in combination, to treat human diseases or disorders, including... More	12.00 %	Net Sales	Copyrights
5	31085	2834	ChemoCentryx, Inc. / Glaxo Group Ltd.	2006	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug can... More	18.00 %	Net Sales	Copyrights
6	31077	2834	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and... More	25.00 %	Net Sales	Copyrights
7	31067	2834	ChemoCentryx, Inc. / Glaxo Group Ltd.	2006	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug can... More	22.00 %	Net Sales	Copyrights

Industry:	Pharmaceutical & Biotech	Refine Search	(3983 Hits)
Sub-Industry:	Gastro Intestinal		(123 Hits)
Agreement Type:	Patent	Refine Search	(107 Hits)
Agreement Type Excluding:	Franchise, Asset Purchase, Amendment	Refine Search	(83 Hits)
Royalty Base:	Net Sales	Refine Search	(79 Hits)
Related Parties:	Exclude		(76 Hits)

We found 76 agreements matching your search criteria.

Rank	Patent No.	Year	Patent Title	Term (Years)	Abstract	Revenue %	Revenue Type	IP Type
1.	31129	2035	The Penn State Research Foundation / Innovive Pharmaceuticals, Inc.	20	Exclusive patent and know-how license to make, have made, use, lease, sell, practice, have practiced and sublicense products and processes related to opioid growth factor, taxanes, and gemcitabine to treat cancer, f... More	10.00 %	Net Sales	Copyrights
2.	31096	2034	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and... More	6.00 %	Net Sales	Copyrights
3.	31094	2034	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and... More	20.00 %	Net Sales	Copyrights
4.	31091	2034	Rapivis, Inc. / Pfizer Inc.	20	Exclusive patent, know-how and technology license to manufacture, use, sell, offer, import and sublicense VR-1 antagonists, either as a single agent or in combination, to treat human diseases or disorders, including... More	12.00 %	Net Sales	Copyrights
5.	31085	2034	ChemoCentryx, Inc. / Glaxo Group Ltd.	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug can... More	18.00 %	Net Sales	Copyrights
6.	31077	2034	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and... More	25.00 %	Net Sales	Copyrights
7.	31067	2034	ChemoCentryx, Inc. / Glaxo Group Ltd.	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug can... More	22.00 %	Net Sales	Copyrights

8.	31038	2834	Midatech Ltd.; MonoSol Rx, LLC / MonoSol Rx, LLC; Midatech Ltd.	2008	20	Collaborative development to integrate nanoparticles and self-dissolving oral thin film technologies, with exclusive patent, know-how, process and technology cross-licenses to develop, manufacture, commercialize and... More	10.00 %	Net Sales	Copyrights
9.	30872	2834	Cornell University, represented by the Cornell Center for Technology Enterprise and Commercialization / BioPancreate, Inc.	2011	20	Exclusive patent, process and technology license to make, have made, use, have used, sell, have sold, offer, have offered, import, have imported and sublicense products related to commensal bacteria as signal mediators... More	2.50 %	Net Sales	Copyrights
10.	30841	3841	Comvita New Zealand Ltd. / Derma Sciences, Inc.	2010	Perpetual	Patent and know-how license to use the "Medihoney" trademarks to make, use, import, offer, supply, sell, lease, distribute, promote and sublicense products that contain medical honey to treat, mitigate or prevent human... More	11.00 %	Net Sales	Copyrights
11.	30861	2834	Yissum Research Development Co. of the Hebrew University of Jerusalem / Intec Pharmaceutical Partnership Ltd.	2000	20	Exclusive patent, know-how and technology license to develop, manufacture, market and sublicense products related to a biodegradable system retained in the stomach to expand the therapeutic potential of drugs having... More	3.00 %	Net Sales	Copyrights
12.	30430	2834	Onconova Therapeutics, Inc. / SymBio Pharmaceuticals Ltd.	2011	20	Exclusive patent, know-how and process license to develop, manufacture, use, sell, offer, import, market, distribute, promote and sublicense pharmaceutical preparations for human use which contain an oncology compound... More	20.00 %	Net Sales	Copyrights
13.	30163	8731	The General Hospital Corp. d/b/a Massachusetts General Hospital / Viacell Endocrine Science, Inc., a subsidiary of ViaCell, Inc.	2002	20	Exclusive patent, know-how, process and technical information license to make, have made, use, sell, offer, import and sublicense products related to pancreatic stem cells for transplantation or to treat diabetes, etc... More	2.00 %	Net Sales	Copyrights
14.	29344	2834	RegeneRx Biopharmaceuticals, Inc. / Defiant Pharmaceuticals Ltd.	2004	20	Exclusive patent, know-how, process and technology license to use, produce, have produced, sell and sublicense prescription or over-the-counter pharmaceutical products and medical devices containing the Thymosin Beta... More	8.75 %	Net Sales	India Presentation Copyrights
15.	29135	2838	Alkermes, Inc., licensee of The Children's Hospital Research Foundation and Children's Hospital, Inc. / Targeted Genetics Corp.	1999	20	Exclusive patent and technology sublicense to make, have made, use, lease, have sold, sell and sublicense products which utilize the C12 adeno-associated virus cell-line to treat and prevent pulmonary disease, infection... More	6.00 %	Net Sales	Copyrights
16.	28862	2836	Senetek PLC / Ardana Bioscience Ltd.	2004	20	Exclusive patent, copyright, proprietary information, process and trademark license to use, manufacture, market, sell, distribute and sublicense a pharmaceutical product for the local treatment of erectile dysfunction... More	12.00 %	Net Sales	Copyrights
17.	28856	2836	Senetek PLC / Ardana Bioscience Ltd.	2004	20	Exclusive patent, copyright, proprietary information, process and trademark license to use, manufacture, market, sell, distribute and sublicense a pharmaceutical product for the local treatment of erectile dysfunction... More	10.00 %	Net Sales	Copyrights
18.	28312	2834	UOP LLC / ZS Pharma, Inc.	2011	20	Exclusive patent, process and technology license to practice, research, develop, make, have made, use, sell, have sold, offer, import, export, market, commercialize, exploit and sublicense products for removing toxins... More	5.00 %	Net Sales	Copyrights
19.	28159	2834	University of Massachusetts / Amaranthus Bioscience Holdings, Inc.	2013	20	Exclusive patent license to develop, have developed, make, have made, use, have used, import, have imported, sell, have sold, and sublicense products and services related to soluble MANF in pancreatic beta-cell dysfunction... More	2.00 %	Net Sales	Copyrights

20.	27906	2834	CIMA Labs Inc. / Schwarz Pharma, Inc.	2001	20	Exclusive patent, know-how, and technology license to use the "CIMA," "DuraSolv," "PakSolv," "OraSolv" and "Meltabs" trademarks to market, distribute, sell and sublicense pharmaceutical prescription products contain... More	5.00 %	Net Sales	Copyrights
21.	27881	2834	Santarus, Inc. / Glaxo Group Ltd.	2007	Perpetual	Exclusive patent, know-how and process license to sell, offer, import and sublicense pharmaceutical products incorporating omeprazole in combination with buffering agents, as capsules, powder for oral suspension or ... More	27.50 %	Net Sales	Javier - 11042014 Copyrights
22.	27663	2834	Oklahoma Medical Research Foundation; The University of Kentucky Research Foundation / Centaur Pharmaceuticals, Inc.	1992	20	Exclusive patent, know-how, process and technology license to make, have made, use, lease, practice, sell and sublicense products related to spin-trapping compounds and phenylbutyl compositions, to treat oxidative t... More	3.00 %	Net Sales	Copyrights
23.	27559	2834	Vanderbilt University / NephroGenex, Inc.	2006	20	Exclusive patent and process license to make, have made, use, sell, offer, import and sublicense products for therapeutic application of pyridoxamine in acute renal failure and other critical illnesses where the occ... More	3.00 %	Net Sales	Copyrights
24.	25885	2834	Raven Biotechnologies, Inc. / ImmunoGen, Inc.	2001	20	Collaborative research program, with exclusive patent and know-how license to develop, make, have made, use, sell, offer, have sold, import, have imported and sublicense pharmaceutical products to treat cancer in hu... More	5.50 %	Net Sales	Copyrights
25.	25843	2834	Raven Biotechnologies, Inc. / ImmunoGen, Inc.	2001	20	Collaborative research program, with exclusive patent and know-how license to develop, make, have made, use, sell, offer, have sold, import, have imported and sublicense pharmaceutical products to treat cancer in hu... More	9.50 %	Net Sales	Copyrights
26.	25640	2836	Onyx Pharmaceuticals, Inc. / Warner-Lambert Co.	1999	20	Collaboration program with exclusive patent license to make, have made, use, offer, sell, have sold, import and sublicense products consisting of a genetically engineered adenovirus that replicates in and kills cano... More	13.00 %	Net Sales	
27.	23887	2834	Novacea, Inc. / Schering Corp.	2007	20	Exclusive patent, know-how, process and technology license to develop, make, have made, use, commercialize, market, promote, distribute, offer, sell, import, export and sublicense pharmaceutical products containing ... More	24.00 %	Net Sales	Javier - 11042014 Miguel
28.	23828	2841	Tri-Point Medical Corp. / Ethicon, Inc.	1996	20	Exclusive patent, know-how and process license to use, market, advertise, promote, distribute, sell and sublicense the "TraumaSeal" topical liquid suture, which is a non-absorbable, formulated, 2-octylcyanoacrylate ... More	5.00 %	Net Sales	
29.	22858	2836	Organogenesis Inc. / Sandoz Pharma Ltd.	1996	20	Exclusive patent license to use, import, sell, offer and sublicense the "Graftskin" skin and tissue equivalent products, designed to mimic the structure and function of human skin, intended for use in venous stasis ... More	12.00 %	Net Sales	
30.	22778	2834	Dr. Falk Pharma GmbH; Ovemed GmbH / Coronado Biosciences, Inc.	2012	20	Collaboration agreement, with exclusive patent, process and know-how license to use, develop, commercialize, sell, offer, import, and sublicense pharmaceutical products containing Trichuris suis ova as the active in... More	1.00 %	Net Sales	

☐ (82)
 ☐ (56)
 ☐

1 2 3 Next >

Rows to display: 30

All	76	1,000	5,000	7,000	9,201	7,688	11,750	6,764	34,000
-----	----	-------	-------	-------	-------	-------	--------	-------	--------



ROYALTYSTAT®

DATABASE | ADMIN | CONTACT | LOG OUT

DASHBOARD | SEARCH | MY ACCOUNT | FEATURES

Search Results

RSID: 15927, 18010, 15906, 15990, 15905, 15928, 16228, 16244, 13775, 14928, 14929, 15020, 28471, 28470

(14 Hits)

Royalty Base: Net Sales Refine Search

(14 Hits)

We found 14 agreements matching your search criteria.

Rank	RSID	Agreement ID	Parties	Year	Term	Description	Rate	Base	IP Type	Geography
1.	28471	2834	Cruceil Holland BV / Vascular Biogenics Ltd.	2011	20	Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceutical products consisting of DNA sequences obtained from the PerC6 cells using licensee's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine. Less	2.00 %	Net Sales	Know-how, Patent, Process	Worldwide
2.	28470	2834	Tel Hashomer - Medical Research, Infrastructure and Services Ltd. / Vascular Biogenics Ltd., Dror Harats	2013	20	Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark license to develop, manufacture, sell, market and sublicense products and devices related to enhancing targeting of viral vectors, expression of a gene-of-interest in cells, treatment with VB-201, PAF-like homologs, oxidized phospholipids, endothelial cell specificity, anti-angiogenic adenovirus vectors, and treatment of ischemia, atherosclerosis, vascular disease, inflammatory disease, cancer, glioblastoma, wound healing, and tumor related conditions. Less	1.00 %	Net Sales	Copyrights, Know-how, Patent, Process, Trade Name, Trademark	Worldwide
3.	18010	3980	Gruppo Santony, LLC / Eternal Image	2009	5	Exclusive sublicense to use the "Vatican Observatory" trade name and logo to design, manufacture, sell, distribute and advertise religious themed products for funerary use, including urns, cremation keepsakes, caskets... More	10.00 %	Net Sales	Sublicense, Trade Name	Worldwide with Exception
4.	16244	2836	Vaxcel, Inc. / Connaught Laboratories, Inc.	1995	15	Exclusive patent, technology and know-how license to manufacture, market and sublicense a parenteral injectable vaccine containing the polyoxyethylene/polyoxypropylene copolymer adjuvant known as "CRL-1005" combined... More	6.00 % 6.00 %	Net Sales	Patent, Research, Technology	Worldwide
5.	16228	2836	Vaxcel, Inc. / Medeva Europe Ltd.	1995	2	Option to a co-exclusive patent, technology and know-how license to develop, manufacture, use, distribute and sell an injectable vaccine containing the nonionic copolymer known as "CRL-1005" combined with fluvirina... More	10.00 % 6.00 %	Net Sales	Option, Patent, Research	Unknown

15990	3990	The Cat Fanciers Association, Inc. / Eternal Image, Inc.	2007	2.9	Nonexclusive license to use the "The Cat Fanciers' Association" trademarks, copyrights, and designs to manufacture, distribute, promote and sell a funerary line of branded urns, through mass retailers and funeral hom... More	8.00 %	Net Sales	Copyrights, Trademark	Canada, United States
15928	3990	The American Kennel Club / Eternal Image, LLC	2005	3.1	Nonexclusive license to use the "The American Kennel Club" trademarks and copyrights to manufacture, distribute, promote and sell a funerary line of AKC branded urns, through pet store chains, mass retailers and int... More	10.00 %	Net Sales	Copyrights, Trademark	Canada, United States
15927	3990	Collegiate Licensing Co. / Eternal Image Inc.	Unknown	Unknown	Nonexclusive license to use the Louisiana State University name, trademarks, and indicia to manufacture, advertise, distribute and sell memorial products such as caskets, urns, and vaults.	8.00 %	Net Sales	Copyrights, Trademark	United States
15906	3990	CBS Consumer Products, a division of CBS Broadcasting Inc. / Eternal Image	2007	3.33	Nonexclusive copyright license to use the "Star Trek" trademark to distribute, promote, manufacture and sell caskets, urns, monuments and vaults to funeral homes.	10.00 %	Net Sales	Copyrights, Trademark	Australia, Canada, Europe, Japan, Ni Ze... Mon
15905	3990	Major League Baseball Properties, Inc. / Eternal Image Inc.	2007	2	Amendment to nonexclusive license to use the American and National League, Major League Baseball, and individual baseball clubs' trademarks, copyrights, and logos to manufacture, distribute, promote, advertise and ... More	12.00 %	Net Sales	Amendment, Copyrights, Trademark	United States
15020	2834	Valens Offshore SPV II, Corp. / Biovest International, Inc.	2008	Unknown	Amendment to royalty agreement for patented biologic products to extend maturity date of promissory note.	9.46 % 5.96 %	Net Sales	Amendment, Patent	Unknown
14928	2834	Valens Offshore SPV II Corp. / Biovest International, Inc.	2007	Perpetual	Purchase of rights related with patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma an... More	2.12 %	Net Sales	Asset Purchase, Patent	Worldwid
14928	2834	Valens U.S. SPV I, LLC / Biovest International, Inc.	2007	Perpetual	Agreement pursuant to a Note Purchase to provide a royalty for patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such ... More	2.88 %	Net Sales	Patent	Worldwid
13776	2834	MetaMorphix, Inc. / Wyeth I/K/a American Home Products Corp. (through Genetics Institute, L.L.C. I/K/a Genetics Institute, Inc.	2002	20	Exclusive patent and technology cross-license with royalty-free know-how license to make, have made, use, import, market, offer, and sell the "GDF-8" TGF- β Factor formulations, antibodies, receptors, antisense mole... More	2.00 %	Net Sales	Cross-License, Know-how, Patent, Technology	Unknown

(122) (59)

Rows to display: 30



ROYALTYSTAT®

DATABASE | ADMIN | CONTACT | LOG OFF

DASHBOARD | SEARCH | MY ACCOUNT ▾ | FEATURES ▾

Search Results 1

RSID: 15927, 18010, 15906, 15990, 15905, 15928, 16228, 16244, 13775, 14928, 14929, 15020, 28471, 28470

(14 Hits)

Royalty Base: Net Sales Refine Search

(14 Hits)

We found 14 agreements matching your search criteria.

exclusive patent, know-how and process use to develop, use, import, manufacture, make, offer and sell pharmaceutical products consisting of DNA sequences cloned from the Per.C6 cells using licensee's viral targeting system platform in combination with the genome of a serotype 5 recombinant adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine.	2.00 %	Net Sales	Know-how, Patent, Process	Worldwide	No	Pharmaceutical & Biotech	Cancer, Cardiovascular, Genetic, Vaccines	License Fee, Milestone Payment
Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark license to develop, manufacture, market and sublicense products and processes related to enhancing targeting of viral vectors, expression of a gene-of-interest in cells, treatment with VB-201, PAF-like mimetics, oxidized phospholipids, endothelial specificity, anti-angiogenic adenovirus vectors, and treatment of ischemia, proliferation, vascular disease, inflammatory disease, cancer, glioblastoma, wound healing, tumor related conditions.	1.00 %	Net Sales	Copyrights, Know- how, Patent, Process, Trade Name, Trademark	Worldwide	No	Pharmaceutical & Biotech	Cancer, Cardiovascular, Genetic, Cold & Flu, Inflammation, Virus & Bacteria	Sublicense Royalty
Exclusive sublicense to use the "Vatican Crematorium" trade name and logo to design, manufacture, sell, distribute and advertise religious themed products for funerary use, including urns, cremation keepsakes, etc., More	10.00 %	Net Sales	Sublicense, Trade Name	Worldwide with Exceptions	No	Consumer Products	Stationery	Minimum Royalty, Sublicense Royalty
Exclusive patent, technology and know-how use to manufacture, market and sublicense intravitreal injectable vaccine containing the polyoxyethylene/polyoxypropylene copolymer variant known as "CRL-1005" combined... More	8.00 % 6.00 %	Net Sales	Patent, Research, Technology	Worldwide	Yes	Pharmaceutical & Biotech	Genetic, Vaccines	Milestone Payment, Other Payments
License to a co-exclusive patent, technology know-how license to develop, manufacture, use, distribute and sell an injectable vaccine containing the nonionic polymer known as "CRL-1005" combined with (fluvirina,... More	10.00 % 6.00 %	Net Sales	Option, Patent, Research	Unknown	Yes	Pharmaceutical & Biotech	Assay test, Cold & Flu, Vaccines, Virus & Bacteria	Upfront Payment, Other Payments

designs to manufacture, distribute, promote and sell a funeral line of branded clothing, through mass retailers and funeral homes. More	10.00 %	Net Sales	Copyrights, Trademark	Canada, United States	Yes	Consumer Products	Upfront Payment, Minimum Royalty
exclusive license to use the "The American Idol Club" trademarks and copyrights to manufacture, distribute, promote and sell a variety line of AKC-branded items, through pet chains, mass retailers and Internet. More	8.00 %	Net Sales	Copyrights, Trademark	United States	Yes	Consumer Products	
exclusive license to use the Louisiana State University name, trademarks, and indicia to manufacture, advertise, distribute and sell funeral products such as caskets, urns, and items. More	10.00 %	Net Sales	Copyrights, Trademark	Australia, Canada, Europe, Japan, New Zealand, Norway	Yes	Consumer Products, Broadcasting	Upfront Payment
exclusive copyright license to use the "Star Trek" trademark to distribute, promote, manufacture and sell caskets, urns, monuments and vaults to funeral homes. More	12.00 %	Net Sales	Amendment, Copyrights, Trademark	United States	No	Advertising	
agreement to nonexclusive license to use the American and National Leagues, Major League Baseball, and individual baseball clubs' trademarks, copyrights, and logos to manufacture, distribute, promote, advertise and more. More	9.48 % 5.96 %	Net Sales	Amendment, Patent	Unknown	Yes	Pharmaceutical & Biotech	
agreement to royalty agreement for patented biologic products to extend maturity date of biologic products. More	2.12 %	Net Sales	Asset Purchase, Patent	Worldwide	No	Pharmaceutical & Biotech	Cancer, Gene Therapy, Vaccines, Urinary & Urology, Virus & Bacteria
agreement pursuant to a Note Purchase to provide a royalty for patented pharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous serum vaccines such as for non-Hodgkin's lymphoma and more. More	2.66 %	Net Sales	Patent	Worldwide	No	Pharmaceutical & Biotech	Cancer, Gene Therapy, Vaccines, Urinary & Urology, Virus & Bacteria
exclusive patent and technology cross-license, royalty-free know-how license to make, a made, use, import, market, offer and sell "GDF-8" TGF- β Factor formulations, bodies, receptors, antisense molecules. More	2.00 %	Net Sales	Cross-License, Know-how, Patent, Technology	Unknown	No	Pharmaceutical & Biotech	Vaccines

Rows to display: 80

All 14 1.000 2.030 8.000 6.819 7.023 10.000 3.887 12.000



License Agreements Search

DASHBOARD SEARCH MY ACCOUNT FEATURES

DATABASE ADMIN CONTACT LOG OFF

More search options: ☐ Attributes ☐ Date ☐ Keyword Search ☐ Territory ☐ Intangible Number

Industry

Including

Agreement Type

Including


Royalty Base

Related Parties

NEW RECENT SEARCHES

CREATE FORM

SEARCH



License Agreements Search

More search options: ☐ Attributes ☐ Date ☐ Keyword Search ☐ Territory ☐ Intangible Number

Industry <input type="text"/>	Agreement Type <input type="text"/>	Including <input type="text"/>
Royalty Base <input type="text"/>	Related Parties <input type="text"/>	Including <input type="text"/>
Company Name <input type="text"/>	Reference Num. <input type="text"/>	RSID <input type="text"/>
CIK <input type="text"/>	Licensee Type <input type="text"/>	
Licensor Type <input type="text"/>	NAICS Code <input type="text"/>	
SIC Code <input type="text"/>	Exclusivity <input type="text"/>	
Royalty Rate Range <input type="text"/>	Additional Payments <input type="text"/>	
Tiered Royalty <input type="text"/>	Famous Brand <input type="text"/>	
License Rights <input type="text"/>		
Show Flags <input type="checkbox"/>		

Licensed Territory

Including

Licensor's Territory

Licensee's Territory

SEC Filed Date

Effective Date

From

To

From

To

Duration

Activate Date

Expected Life

Intangible Number Country

Intangible Number

Intangible Number Type

Application Number

Description of Intangibles

Full Text Search

Quick

Advanced

Quick

Advanced



Reference:	L13775	Date: 11/20/2015
CIK:	0001289370	
IRS:	000000000	
SEC Filer Name:	MetaMorphix Inc.	
Agreement Title:	Cross-License Agreement	
Effective Date:	10/14/2002	
Agreement Type:	Cross-License; Know-how; Patent; Technology	
Industry:	Pharmaceutical & Biotech	
SIC Code:	2834	
NAICS Code:	325412	
Licensor:	MetaMorphix, Inc.	
Licensor's Country:	United States	
Licensee:	Wyeth f/k/a American Home Products Corp. through Genetics Institute, L.L.C. f/k/a Genetics Institute, Inc.	
Licensee's Country:	United States	
Royalty Rate:	2.00 %	
Royalty Base:	Net Sales	
Original Base:	Net Sales	
Tiered Royalty:	No	
Duration (Year):	20.0	
Licensed Territory:	Unknown	
Exclusivity:	Exclusive	
Description of Intangibles:	Exclusive patent and technology cross-license with royalty-free know-how license to make, have made, use, import, market, offer, and sell the "GDF-8" TGF- β Factor formulations, antibodies, receptors, antisense molecules, pharmaceutical products, antagonists, vaccines and modulators.	
Comments:	Expansion of exclusive patent and technology cross-license. Secs. 2.1 and 2.2. Nonexclusive royalty-free know-how license. Secs. 2.1 and 2.2. Royalty to each party is 2% of net sales. Secs. 4.1 and 4.2. Royalty is incremental to royalties payable under the 1999 Agreement. Secs. 4.1 and 4.2. Related to AutoID 10600, et al.	



Reference:	L14928	Date: 11/20/2015
GVKEY:	150200	
CIK:	0000704384	
IRS:	411412084	
SEC Filer Name:	BIOVEST INTERNATIONAL INC	
Agreement Title:	Royalty Agreement	
Effective Date:	12/10/2007	
Agreement Type:	Patent	
Industry:	Pharmaceutical & Biotech	
SIC Code:	2834	
NAICS Code:	325412	
Licensor:	Valens U.S. SPV I, LLC	
Licensor's Country:	United States	
Licensee:	Biovest International, Inc.	
Licensee's Country:	United States	
Royalty Rate:	2.88 %	
Royalty Base:	Net Sales	
Original Base:	Net Sales	
Tiered Royalty:	No	
Duration (Year):	Perpetual	
Licensed Territory:	Worldwide	
Exclusivity:	Unknown	
Description of Intangibles:	Agreement pursuant to a Note Purchase to provide a royalty for patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell-based therapies, stem cells, cytokines, and viruses produced by mammalian cell culture techniques.	
Comments:	Royalty agreement for patented products. Art. 4.1. Royalty is 2.88% of net sales. Art. 4.1. Term is as long as Biovest commercializes products. Art. 7.1. Related to AutoIDs 14929, 15020.	



Reference:	L14929	Date: 11/20/2015
GVKEY:	150200	
CIK:	0000704384	
IRS:	411412084	
SEC Filer Name:	BIOVEST INTERNATIONAL INC	
Agreement Title:	Royalty Agreement	
Effective Date:	12/10/2007	
Agreement Type:	Asset Purchase; Patent	
Industry:	Pharmaceutical & Biotech	
SIC Code:	2834	
NAICS Code:	325412	
Licensor:	Valens Offshore SPV II Corp.	
Licensor's Country:	United States	
Licensee:	Biovest International, Inc.	
Licensee's Country:	United States	
Royalty Rate:	2.12 %	
Royalty Base:	Net Sales	
Original Base:	Net Sales	
Tiered Royalty:	No	
Duration (Year):	Perpetual	
Licensed Territory:	Worldwide	
Exclusivity:	Unknown	
Description of Intangibles:	Purchase of rights related with patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell-based therapies, stem cells, cytokines, and viruses produced by mammalian cell culture techniques.	
Comments:	Asset purchase, including patents. Recitals and Sec. 4.1. Royalty is 2.12% of net sales. Sec. 4.1. Term is as long as Biovest commercializes products. Sec. 7.1. Related to AutoIDs 14928 and 15020.	



Reference:	L15020	Date: 11/20/2015
GVKEY:	162956	
CIK:	0001310094	
IRS:	000000000	
SEC Filer Name:	ACCENTIA BIOPHARMACEUTICALS INC	
Agreement Title:	Royalty Agreement Amendment	
Effective Date:	5/30/2008	
Agreement Type:	Amendment; Patent	
Industry:	Pharmaceutical & Biotech	
SIC Code:	2834	
NAICS Code:	325412	
Licensor:	Valens Offshore SPV II, Corp.	
Licensor's Country:	Unknown	
Licensee:	Blovest International, Inc.	
Licensee's Country:	United States	
Royalty Rate:	9.46 %	
Royalty Base:	Net Sales	
Original Base:	Net Sales	
Tiered Royalty:	Yes	
Duration (Year):	Unknown	
Licensed Territory:	Unknown	
Exclusivity:	Unknown	
Description of Intangibles:	Amendment to royalty agreement for patented biologic products to extend maturity date of promissory note.	
Comments:	Letter amendment for license to sell patented products. Royalty is 9.46% of net sales. Royalty will be reduced to 5.96% or 6.96% if licensee pays at least \$10,000,000 to LV Administrative Services, Inc. for its administrative and collateral agent services. Related to AutoID 14929.	



Reference: L16228 Date: 11/20/2015
 GVKEY: 24887
 CIK: 0001029802
 IRS: 58-2027283
 SEC Filer Name: VAXCEL INC.
 Agreement Title: Option Agreement
 Effective Date: 10/13/1995
 Agreement Type: Option; Patent; Research
 Industry: Pharmaceutical & Biotech
 SIC Code: 2836
 NAICS Code: 325414
 Licensor: Vaxcel, Inc.
 Licensor's Country: United States
 Licensee: Medeva Europe Ltd.
 Licensee's Country: United Kingdom
 Royalty Rate: 10.00 %
 Royalty Base: Net Sales
 Original Base: Net Sales
 Tiered Royalty: Yes
 Additional Payments: Upfront Payment; Other Payments
 Duration (Year): 2.0
 Licensed Territory: Unknown
 Exclusivity: Non-Exclusive
 Description of Intangibles: Option to a co-exclusive patent, technology and know-how license to develop, manufacture, use, distribute and sell an injectable vaccine containing the nonionic copolymer known as "CRL-1005" combined with fluvirina, a purified-surface-antigen influenza virus vaccine, to enhance the immune response in humans through Phase I human clinical trials.
 Other Payments: Payment is \$90,000 upon signing. Sec. 4.1. Payment is \$250,000 if an IND or CTX for the product has not been submitted to any 1 regulatory agency within 1 year from the effective date; \$160,000 if an IND or CTX for the product is submitted to any 1 regulatory agency; and \$250,000 upon completion of the Phase I human clinical trials. Secs. 4.2, 4.3 and 4.4. If option is exercised, payment is \$250,000 upon completion of the Phase II human clinical trials; \$300,000 upon completion of the Phase III human clinical trials; \$50,000 per month if Phase II does not commence within 6 months after completion of Phase II; \$300,000 upon each submission of a Product License Application or New Drug Application to the FDA or the MCA; \$1,500,000 upon approval for product commercialization in the United States; \$1,150,000 upon approval for product commercialization in the United Kingdom; \$100,000 upon approval for product commercialization per country other than USA or UK, until \$1,200,000 has been paid. Secs. 6.2.4 through 6.2.9.
 Intangible Number: Patent Appl. No. 08/292,814 "Nonionic Block Copolymers." Appx. 1.

Comments:

Co-exclusive patent, technology and know-how license. Secs. 2.1 and 7.1. Parties shall jointly develop the program for the Phase I clinical trials. Sec. 3.1. Option to license. Sec. 5.1. If option is exercised, payment is \$300,000 for the supply agreement. Sec. 6.2.1. Royalty is between 6% and 10% of net sales, depending on the efficacy profile and production benefits of the product. Sec. 6.2.13.



Reference: L16244 Date: 11/20/2015

GVKEY: 24887

CIK: 0001029802

IRS: 58-2027283

SEC Filer Name: VAXCEL INC

Agreement Title: Feasibility Evaluation/Development Option Agreement

Effective Date: 8/4/1995

Agreement Type: Patent; Research; Technology

Industry: Pharmaceutical & Biotech

SIC Code: 2836

NAICS Code: 325414

Licensor: Vaxcel, Inc.

Licensor's Country: United States

Licensee: Connaught Laboratories, Inc.

Licensee's Country: United States

Royalty Rate: 8.00 %

Royalty Base: Net Sales

Original Base: Net Sales

Tiered Royalty: Yes

Additional Payments: Milestone Payment; Other Payments

Duration (Year): 15.0

Licensed Territory: Worldwide

Exclusivity: Exclusive

Description of Intangibles: Exclusive patent, technology and know-how license to manufacture, market and sublicense a parenteral injectable vaccine containing the polyoxyethylene/polyoxypropylene copolymer adjuvant known as "CRL-1005" combined with recombinant lipidated outer surface protein A "OspA" from *Borrelia burgdorferi*, the causative agent of Lyme disease.

Other Payments: Payment to evaluate the product is \$25,000 upon signing. Sec. 2.2. If preclinical evaluation is successful, payment is \$20,000 for exclusive development rights through Phase I clinical trials. Sec. 2.2. Milestone payments are \$250,000 upon beginning of Phase II; \$250,000 upon beginning of Phase III; \$500,000 upon PLA filing; \$1,000,000 upon FDA/CBER approval; \$100,000 per country regulatory approval up to \$500,000. Sec. 4.

Comments: Exclusive patent, technology and know-how license. Recitals and Sec. 4. Parties shall jointly develop the program. Sec. 2.1. After the program, parties shall negotiate a license agreement. Sec. 4. License issue fee is \$500,000. Sec. 4. Royalty will be between 6% and 8% of net sales. Sec. 4. Duration of the agreement is 2 years, but future license is for the life of patents, Secs. 4 and 6.1.



Reference: L28470 Date: 11/20/2015
 GVKEY: 21209
 CIK: 0001603207
 IRS: 000000000
 SEC Filer Name: Vascular Biogenics Ltd.
 Agreement Title: Agreement
 Effective Date: 02/03/2013
 Agreement Type: Copyrights; Know-how; Patent; Process; Trade Name; Trademark
 Industry: Pharmaceutical & Biotech
 SIC Code: 2834
 NAICS Code: 325412
 Licensor: Tel Hashomer - Medical Research, Infrastructure and Services Ltd.
 Licensor's Country: Israel
 Licensee: Vascular Biogenics Ltd.; Dror Harats
 Licensee's Country: Israel
 Royalty Rate: 1.00 %
 Royalty Base: Net Sales
 Original Base: Net Sales
 Tiered Royalty: No
 Additional Payments: Sublicense Royalty
 Duration (Year): 20.0
 Licensed Territory: Worldwide
 Exclusivity: Unknown
 Description of Intangibles: Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark license to develop, manufacture, sell, market and sublicense products and devices related to enhancing targeting of viral vectors, expression of a gene-of-interest in cells, treatment with VB-201, PAF-like homologs, oxidized phospholipids, endothelial cell specificity, anti-angiogenic adenovirus vectors, and treatment of ischemia, atherosclerosis, vascular disease, inflammatory disease, cancer, glioblastoma, wound healing, and tumor related conditions.
 Intangible Number: Patent and Appl. Nos. PCT WO2011/083469 "Treatment with VB-201;" WO2009/050692 "PAF-Like Homologs And Uses Thereof;" WO2006/006161, IL 180628, JP 4,767,948, KR 10-1201935, CN 200580029218.9, RU 2399626, MX 284830, 303011, AU 2007200090, "Improved Process For The Preparation Of Oxidized Phospholipids;" US 7,067,649, 7,579,327, PCT IL03/00347, SG 200406381-4, ZA 2004/8989, JP 2004-501545, CA 2,483,996, MX PA/a/2004/010711 "Promoters Exhibiting Endothelial Cell Specificity And Methods Of Using Same;" PCT WO2011/083467 "Combined Treatment Utilizing VB-201;" PCT WO/2008/015675, CN ZL20078003 5863.0, AU 2007280017, NZ 574410, ZA 2009/00581, SG 149616(WO2008/015675) "Polypeptides And Polynucleotides Encoding Same And Use Thereof In The Treatment Of Medical Conditions Associated With Ischemia." See Appx. B for complete list.

<http://www.royaltystat.com>

Copyright © 2015 RoyaltyStat® All Rights Reserved

Distribution of this document is restricted under RoyaltyStat's Terms of Use.

Comments:

Settlement of dispute. Recitals. Patent, know-how, process, copyrights, trade names and trademark license. Sec. 1.3.8. Right to sublicense. Sec. 3.1. Royalty is 1% of net sales. Sec. 4.1.1. Sublicense consideration is 2% of license fees. Sec. 4.1.2. Net sales include sales by sublicensees. Sec. 1.3.9. Sublicense fees include lump sums, license fees and milestone payments. Sec. 1.3.9. Term is the later of life of the patents or 15 years from 1st commercial sale in each country. Sec. 4.1.



Reference:	L28471	Date: 11/20/2015
GVKEY:	21209	
CIK:	0001603207	
IRS:	000000000	
SEC Filer Name:	Vascular Biogenics Ltd.	
Agreement Title:	Commercial Gene Therapy License Agreement	
Effective Date:	4/15/2011	
Agreement Type:	Know-how; Patent; Process	
Industry:	Pharmaceutical & Biotech	
SIC Code:	2834	
NAICS Code:	325412	
Licensor:	CruceII Holland BV	
Licensor's Country:	Netherlands, Netherlands	
Licensee:	Vascular Biogenics Ltd.	
Licensee's Country:	Israel, Israel	
Royalty Rate:	2.00 %	
Royalty Base:	Net Sales	
Original Base:	Net Sales	
Tiered Royalty:	No	
Additional Payments:	License Fee; Milestone Payment	
Duration (Year):	20.0	
Licensed Territory:	Worldwide	
Exclusivity:	Non-Exclusive	
Description of Intangibles:	Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceutical products consisting of DNA sequences obtained from the Per.C6 cells using licensee's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine.	
Other Payments:	Licensee fee is 75,000 Euros. Sec. 4.1.1. License maintenance fee is 100,000 Euros annually. Sec. 4.1.2. Milestone payments are non-creditable and are 400,000 Euros upon approval of 1st indication for each product. Sec. 4.2.	
Comments:	Nonexclusive patent, know-how and process license. Sec. 2.1. Royalty is 1.5% of net sales for products covered by know-how, 0.5% of net sales for products covered by a patent, and a total of 2% of net sales for products covered by both. Sec. 4.3. Royalty for products covered only by know-how will be due for 10 years from 1st commercial sale. Sec. 4.3.1.	



[DATABASE](#)
[ADMIN](#)
[CONTACT](#)
[LOG OUT](#)

[DASHBOARD](#)
[SEARCH](#)
[MY ACCOUNT](#)
[FEATURES](#)

Contractual Terms

Exclusivity

▼

All Agreements

▼

Net Sales %

▼


Display

▼

Download as

▼

UNFILTERED ROYALTY RATES





[HOME](#) |
 [ABOUT](#) |
 [CONTACT](#) |
 [LOG OUT](#)

[DASHBOARD](#) |
 [SEARCH](#) |
 [MY ACCOUNT](#) |
 [FEATURES](#)

Contractual Terms

Industry


All Agreements

Net Sales %

Display

Download as

UNFILTERED ROYALTY RATES





ROYALTYSTAT®

[DATABASE](#) | [ADMIN](#) | [CONTACT](#) | [LOG OUT](#)

[DASHBOARD](#) | [SEARCH](#) | [MY ACCOUNT](#) ▾ | [FEATURES](#) ▾

Contractual Terms

License Rights ▾


All Agreements ▾

Net Sales % ▾

Display ▾

Download as ▾

UNFILTERED ROYALTY RATES



[Database](#) |
 [Admin](#) |
 [Contact](#) |
 [Logout](#)




[Dashboard](#) |
 [Search](#) |
 [My Account](#) |
 [Features](#)

Contractual Terms

Territory - Region
All Agreements
Net Sales %
Display
Download as

UNFILTERED ROYALTY RATES





Contractual Terms

Tiered Royalty Rate

All Agreements

Net Sales %

Display

Download as

UNFILTERED ROYALTY RATES

